

CITATION REPORT

List of articles citing

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

DOI: 10.1016/s0140-6736(20)31022-9
Lancet, The, 2020, 395, 1569-1578.

Source: <https://exaly.com/paper-pdf/77478866/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2258	Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. 2020 , 7, ofaa320		
2257	Treatment of coronavirus disease 2019. 2020 , 15, 336-340		3
2256	Effect of traditional Chinese medicine injections on severe pneumonia: A protocol for systematic review and meta-analysis. 2020 , 99, e22012		2
2255	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). 2020 , 29,		50
2254	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. 2020 , 7, 546		5
2253	Drug Weaponry to Fight Against SARS-CoV-2. 2020 , 7, 204		2
2252	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 1-112		2
2251	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. 2020 , 80, 1929-1946		45
2250	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. 2020 , 49, 763-773		13
2249	Favipiravir-induced fever in coronavirus disease 2019: A report of two cases. 2020 , 101, 188-190		5
2248	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. 2020 , 89, 107082		10
2247	Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?. 2021 , 73, e847-e848		1
2246	Impact of primary culture: A true positive culture rate mystery. 2020 , 60, 2459-2460		
2245	Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. 2020 , 7, 586221		30
2244	Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19. 2020 , 53, 1108-1122.e5		107
2243	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. 2020 , 182, 114225		40
2242	COVID-19 associated complications and potential therapeutic targets. 2020 , 886, 173548		10

2241	Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes. 2020 ,	13
2240	Critically-ill pediatric patients with COVID-19. An update. 2020 , 118, e454-e462	
2239	Acute Kidney Injury in COVID-19: The Chinese Experience. 2020 , 40, 430-442	17
2238	COVID-19 in the Pediatric Population-Review and Current Evidence. 2020 , 22, 29	12
2237	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. 2020 , 27, 100547	17
2236	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. 2020 , 11, 1224	17
2235	Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis. 2020 , 11, 540187	2
2234	Remdesivir and COVID-19. <i>Lancet, The</i> , 2020 , 396, 953-954	40 5
2233	Remdesivir and COVID-19. <i>Lancet, The</i> , 2020 , 396, 953	40 6
2232	Remdesivir and COVID-19. <i>Lancet, The</i> , 2020 , 396, 952	40 9
2231	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. 2021 , 8, 385-400	18
2230	Opinions on the current pandemic of COVID-19: Use functional food to boost our immune functions. 2020 , 13, 1811-1817	11
2229	The use of remdesivir outside of clinical trials during the COVID-19 pandemic. 2020 , 13, 61	2
2228	The Potential of Antiviral Peptides as COVID-19 Therapeutics. 2020 , 11, 575444	31
2227	COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. 2020 , 261, 118336	35
2226	Pandemic treatments on trial: the bigger picture.. 2020 , 56,	2
2225	Antivirals Against SARS-CoV2: Relevance to the Treatment of Alzheimer's Disease. 2020 , 78, 905-906	3
2224	Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. 2020 , 9, 2433-2445	86

2223	The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. 2020 , 95,	91
2222	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. 2021 , 39, 119-139	36
2221	Critical Care Demand and Intensive Care Supply for Patients in Japan with COVID-19 at the Time of the State of Emergency Declaration in April 2020: A Descriptive Analysis. 2020 , 56,	1
2220	Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. 2020 , 14, 1563-1569	55
2219	Buying Time for an Effective Epidemic Response: The Impact of a Public Holiday for Outbreak Control on COVID-19 Epidemic Spread. 2020 , 6, 1108-1114	18
2218	Strategies and Advances in Combating COVID-19 in China. 2020 , 6, 1076-1084	8
2217	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541	4
2216	Critical reappraisal of remdesivir investigational trials in COVID-19. 2020 , 38, 100745	1
2215	COVID-19 in a patient with a flare of systemic lupus erythematosus: A rare case-report. 2020 , 31, 101252	7
2214	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. 2020 , 11, 5284	45
2213	Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations. 2020 , 1-14	16
2212	The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak. 2020 , 7, 552991	
2211	Detection of COVID-19 Using Deep Learning Algorithms on Chest Radiographs. 2020 , 35, 369-376	4
2210	Immunomodulation Through Low-Dose Radiation for Severe COVID-19: Lessons From the Past and New Developments. 2020 , 18, 1559325820956800	5
2209	Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. 2020 , 63, 101942	39
2208	Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2. 2020 , 550, 61-69	22
2207	Metallo drug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. 2020 , 5, 1439-1448	76
2206	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 [A PHARMACOLOGICAL REVIEW]. 2020 , 42-50	

2205	Debate on Bacille Calmette-Guérin vaccination against COVID-19: Is it worth performing clinical trials?. 2020 , 2, 113-114	2
2204	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. 2020 , 33, 108254	107
2203	Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. 2020 , 889, 173634	21
2202	Molecular dynamics analysis predicts ritonavir and naltrexone strongly block the SARS-CoV-2 spike protein-hACE2 binding. 2020 , 1-10	7
2201	A Review of Remdesivir for COVID-19: Data to Date. 2020 , 28, 332-334	5
2200	Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. <i>Lancet, The</i> , 2020 , 396, 1310-1311	40 10
2199	Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: a multicentre retrospective study. 2020 , 148, e238	18
2198	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. 2021 , 73, e3996-e4004	43
2197	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. 2020 , 9, 1988-1996	30
2196	Projected supportive effects of Pycnogenol in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection. 2020 , 56, 106191	2
2195	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
2194	Remdesivir against COVID-19 and Other Viral Diseases. 2020 , 34,	97
2193	COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence. 2020 , 11, 579415	9
2192	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008	39
2191	Potential nanoparticle applications for prevention, diagnosis, and treatment of COVID-19. 2020 , 1, 20200105	7
2190	Diagnostic technologies for COVID-19: a review.. 2020 , 10, 35257-35264	14
2189	Recent Advances in 1,2,4-Triazole Scaffolds as Antiviral Agents. 2020 , 5, 11654-11680	17
2188	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. 2020 , 15, 1467-1476	28

2187	Remdesivir and COVID-19 - Authors' reply. <i>Lancet, The</i> , 2020 , 396, 954	40	1
2186	Remdesivir and COVID-19. <i>Lancet, The</i> , 2020 , 396, 952	40	0
2185	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. 2020 , 32, 3159-3166		9
2184	Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations. 2020 , 23, 1409-1422		6
2183	SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. 2020 , 11, 4938		122
2182	Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. 2020 , 11, 4968		105
2181	Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. 2020 , 383, 1645-1656		38
2180	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. 2020 , 117, 27141-27147		91
2179	Reply to Olivera and Mallat. 2021 , 73, e272-e273		
2178	In the Fog of COVID. 2020 ,		
2177	An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. 2020 , 13, 1405-1414		21
2176	[Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection]. 2020 , 155, 448-453		7
2175	[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. 2020 , 155, 375-381		5
2174	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. 2020 , 17, 543-558		560
2173	Machine learning for clinical trials in the era of COVID-19. 2020 , 12, 506-517		24
2172	US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue. 2020 , 370, m2797		4
2171	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. 2020 , 6, 2304-2318		25
2170	Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. 2021 , 87, 3439-3450		14

2169	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. 2020 , 18, 2629-2635	53
2168	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. 2020 , 79, 1143-1151	137
2167	Repurposing Existing Drugs for the Treatment of COVID-19. 2020 , 17, 1186-1194	15
2166	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. 2020 , 8, 384	7
2165	Kurarinone Inhibits HCoV-OC43 Infection by Impairing the Virus-Induced Autophagic Flux in MRC-5 Human Lung Cells. 2020 , 9,	7
2164	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
2163	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. 2020 , 190, e274-e276	13
2162	A Randomized Clinical Trial of the Efficacy and Safety of Interferon β 1a in Treatment of Severe COVID-19. 2020 , 64,	170
2161	Evidence-based medicine and COVID-19: what to believe and when to change. 2020 , 37, 572-575	25
2160	A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection. 2020 , 11, 1736	26
2159	A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study. 2020 , 7, 2001435	20
2158	Covid-19: Experts criticise claim that remdesivir cuts death rates. 2020 , 370, m2839	4
2157	In reply-The "Perfect Cytokine Storm" of COVID-19. 2020 , 95, 2037-2038	2
2156	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. 2020 , 53, 100719	79
2155	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. 2020 , 203, 112647	17
2154	The efficacy of acupuncture for improving the side effects of COVID-19 western medicine treatments: A protocol for a systematic review and meta-analysis. 2020 , 99, e21185	2
2153	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. 2020 , 2, 1-12	11
2152	The epidemiology and therapeutic options for the COVID-19. 2020 , 3, 71-84	7

2151	Endpoints for randomized controlled clinical trials for COVID-19 treatments. 2020 , 17, 472-482	28
2150	Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. 2020 , 24, 438	39
2149	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. 2020 , 11, 1660	28
2148	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. 2020 , 21,	22
2147	Clinical presentation and management of COVID-19. 2020 , 213, 134-139	24
2146	Pathogenesis and management of myocardial injury in coronavirus disease 2019. 2020 , 22, 1994-2006	19
2145	The dynamic treatment of SARS-CoV-2 disease. 2020 , 33, 572-579	1
2144	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. 2020 , 12, 483-497	22
2143	Urgent call for greater multilateralism and coordination of covid-19 trials. 2020 , 370, m2666	
2142	Could Ergothioneine Aid in the Treatment of Coronavirus Patients?. 2020 , 9,	29
2141	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. 2020 , 46, 2265-2283	27
2140	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. 2020 , 9, 525-536	14
2139	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). 2020 , 7, 572485	10
2138	Current and Future Direct-Acting Antivirals Against COVID-19. 2020 , 11, 587944	10
2137	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. 2020 , 6, 6540-6555	13
2136	An Acute Pulmonary Coccidioidomycosis Coinfection in a Patient Presenting With Multifocal Pneumonia With COVID-19. 2020 , 8, 2324709620972244	11
2135	Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. 2020 , 11, 587709	6
2134	Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. 2020 , 34, 525-541	11

2133 Research on Covid-19 from Biophysical Perspective. **2020**, 1-14

2132 The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. **2020**, 21, 11

2131 Overcoming nonstructural protein 15-nidoviral uridylyate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2. **2020**, 2, FDD42 6

2130 Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity. **2020**, 26, 341 17

2129 Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. **2021**, 72, e1130-e1143 14

2128 . **2020**, 192, E1585-E1596 2

2127 Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. **2020**, 62, 103132 39

2126 [COVID-19 pneumonia]. **2020**, 15, 1-11 2

2125 Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort. **2020**, 41, 732-740 7

2124 COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis. **2020**, 14, 5097-5108 4

2123 Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review. **2021**, 87, 2663-2684 8

2122 Recommendations for treatment of critically ill patients with COVID-19 : Version 3 S1 guideline. **2020**, 1 11

2121 Repurposing Anti-Cancer Drugs for COVID-19 Treatment. **2020**, 14, 5045-5058 14

2120 The role of artificial intelligence in tackling COVID-19. **2020**, 15, 717-724 37

2119 Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. **2020**, 7, 2054358120967845 9

2118 Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections. **2020**, 8, 594458 19

2117 Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development. **2020**, 9, 0

2116 How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. **2020**, 173, 632-637 20

2115	Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study. 2020 , 161, 105290	33
2114	Post liver transplant recurrent and de novo viral infections. 2020 , 46-47, 101689	4
2113	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. 2020 ,	57
2112	Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study. 2020 , 2, e0263	2
2111	COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies. 2020 , 11, 1481-1495	6
2110	MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti-COVID-19 Therapeutics. 2020 , 11, 582003	11
2109	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. 2020 , 155, 375-381	1
2108	Remdesivir: a pendulum in a pandemic. 2020 , 371, m4560	2
2107	Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol. 2020 , 10, e040580	15
2106	FDA efficiency for approval process of COVID-19 therapeutics. 2020 , 15, 73	5
2105	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. 2020 , 8,	14
2104	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. 2020 , 25,	8
2103	Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. 2020 , 11, 10482-10488	16
2102	Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19. 2020 , 7, ofaa481	12
2101	USA stockpiling of remdesivir: How should the world respond?. 2020 , 9, 1243-1246	
2100	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. 2020 , 11, 588409	11
2099	The "sex gap" in COVID-19 trials: a scoping review. 2020 , 29, 100652	21
2098	The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review. 2020 , 88, 55	3

2097	Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. 2020 , 3, 2000156	9
2096	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. 2020 , 8,	8
2095	Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection : A Retrospective Cohort Study. 2020 , 173, 782-790	95
2094	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. 2020 , 173, 623-631	298
2093	Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. 2020 , 155, 448-453	0
2092	Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2. 2020 , 3, 1361-1370	9
2091	COVID-19: a review. 2020 , 5, e07-e07	
2090	Coronavirus Infection of the Central Nervous System: Animal Models in the Time of COVID-19. 2020 , 7, 584673	2
2089	Tratamientos farmacológicos de los pacientes con COVID19: interacciones e indicaciones. 2020 , 20, 33-39	
2088	Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. 2020 , 11, 776-782	50
2087	COVID-19: Therapeutics and interventions currently under consideration. 2020 , 66, 101058	8
2086	The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. 2020 , 21, 225	134
2085	A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. 2020 , 14, 3215-3222	33
2084	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,	16
2083	Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19. 2020 , 21, 742-743	2
2082	30-Year-Old Woman With Cough, Dyspnea, and Anosmia. 2020 , 95, 1775-1779	
2081	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. 2020 , 30, 1-13	12
2080	Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. 2020 , 219, 108555	66

2079	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451	54
2078	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. 2020 , 887, 173467	12
2077	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. 2020 , 88, 106885	20
2076	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114	11
2075	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. 2020 , 21, 1821-1849	3
2074	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,	11
2073	Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. 2020 , 76, 442-453	107
2072	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. 2020 , 13, 1187-1195	46
2071	Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. 2020 , 9,	26
2070	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. 2020 , 35, 725-733	20
2069	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. 2020 , 15, e0236778	14
2068	Integrating the evidence: confronting the COVID-19 elephant. 2020 , 46, 1904-1907	3
2067	COVID-19 zugzwang: Potential public health moves towards population (herd) immunity. 2020 , 1, 100031	17
2066	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. 2021 , 73, e4166-e4174	72
2065	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. 2020 , 13,	47
2064	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
2063	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.. 2020 , 10, 26895-26916	20
2062	Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. 2020 , 11, 1723	33

2061	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. 2020 , 11, 820	12
2060	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. 2020 , 6, 1-13	10
2059	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. 2020 , 2, 100159	22
2058	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. 2020 , 99, 28-33	40
2057	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. 2020 , 26, 1983-1994	26
2056	COVID-19 and the Kidneys: An Update. 2020 , 7, 423	48
2055	[COVID-19 pneumonia]. 2020 , 61, 793-803	5
2054	Liver injury in remdesivir-treated COVID-19 patients. 2020 , 14, 881-883	47
2053	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020 , 59, 1195-1216	18
2052	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). 2020 , 58, 102887	78
2051	Potential role of medicinal plants and their constituents in the mitigation of SARS-CoV-2: identifying related therapeutic targets using network pharmacology and molecular docking analyses.. 2020 , 10, 27961-27983	24
2050	Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer. 2020 , 18, 492-502	4
2049	Remdesivir for severe covid-19: a clinical practice guideline. 2020 , 370, m2924	58
2048	Drug treatments for covid-19: living systematic review and network meta-analysis. 2020 , 370, m2980	331
2047	SARS-CoV-2: characteristics and current advances in research. 2020 , 17, 117	39
2046	Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis. 2020 , 24, 464	32
2045	Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. 2020 , 11, 1069-1081	21
2044	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. 2020 , 28, 745-764	9

2043	Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. 2020 , 23, 100403	22
2042	Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. 2020 , 18, 385-394	39
2041	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
2040	Desperate times call for evidence-based measures: Prioritizing science during the COVID-19 pandemic. 2020 , 5, 127-129	
2039	Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic. 2020 , 897190020942658	5
2038	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. 2020 , 56, 106129	7
2037	Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. 2020 , 60, 328-333	25
2036	Remdesivir: Remedy the world is waiting for?. 2020 , 76, 250-252	
2035	Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. 2020 , 79, 710-727	163
2034	COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. 2020 , 71, 2191-2194	14
2033	Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis. 2020 , 99, e21404	6
2032	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. 2020 , 11, 1991	56
2031	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. 2020 , 885, 173450	9
2030	Improvement of the C-glycosylation Step for the Synthesis of Remdesivir. 2020 , 24, 1772-1777	21
2029	Mathematical Modeling of Business Reopening When Facing SARS-CoV-2 Pandemic: Protection, Cost, and Risk. 2020 , 6,	1
2028	Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic. 2020 , 85, 102481	5
2027	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. 2020 , 180, 114184	32
2026	Safety profile of the antiviral drug remdesivir: An update. 2020 , 130, 110532	43

2025	Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. 2020 , 18, 2835-2836	35
2024	Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. 2020 , 8, e00631	9
2023	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. 2020 , 26, 2181-2189	27
2022	COVID-19 and liver disease: An update. 2020 , 43, 472-480	12
2021	"Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. 2020 , 8,	12
2020	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. 2020 , 7, e737-e745	223
2019	Missed Opportunities on Emergency Remdesivir Use. 2020 , 324, 331-332	12
2018	Occurrence of acute coronary syndrome, pulmonary thromboembolism, and cerebrovascular event in COVID-19. 2020 , 8, 2414	8
2017	Potential diagnostics and therapeutic approaches in COVID-19. 2020 , 510, 488-497	25
2016	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. 2020 , 26, 1436-1446	53
2015	Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history. 2020 , 11, 1015-1023	1
2014	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. 2020 , 9,	1
2013	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,	4
2012	Immune Response and COVID-19: A mirror image of Sepsis. 2020 , 16, 2479-2489	32
2011	Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks. 2020 , 60, 2457-2459	12
2010	Antivirals for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11	4
2009	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240	4
2008	Current Options in the Treatment of COVID-19: A Review. 2020 , 13, 1999-2010	5

2007	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. 2020 , 11, 570927	21
2006	Challenges and future directions of potential natural products leads against 2019-nCoV outbreak. 2020 , 24, 100180	3
2005	The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. 2020 , 2, d1aa053	15
2004	Pharmacy preparedness and response for the prevention and control of coronavirus disease (COVID-19) in Aksum, Ethiopia; a qualitative exploration. 2020 , 20, 913	9
2003	PHARMACOLOGICAL TREATMENTS OF COVID-19 A REVIEW. 2020 , 16-22	2
2002	Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven. 2020 , 20, 100663	
2001	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. 2020 , 11, 2526-2533	98
2000	Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. 2020 , 11, 583006	3
1999	[German recommendations for treatment of critically ill patients with COVID-19-version 3]. 2020 , 17, 1-12	3
1998	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980	20
1997	COSMO-RS-Based Descriptors for the Machine Learning-Enabled Screening of Nucleotide Analogue Drugs against SARS-CoV-2. 2020 , 11, 9408-9414	6
1996	COVID-19-Lessons Learned and Questions Remaining. 2021 , 72, 2225-2240	34
1995	Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. 2020 , 2020, 2560645	61
1994	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
1993	COVID-19 multidisciplinary high dependency unit: the Milan model. 2020 , 21, 260	14
1992	Dexamethasone and remdesivir: finding method in the COVID-19 madness.. 2020 , 1, e309-e310	13
1991	SARS-CoV-2 viral load is associated with increased disease severity and mortality. 2020 , 11, 5493	360
1990	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. 2020 , 60, 840-851	18

1989	Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. 2021 , 31, e2187	36
1988	Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel?. 2020 , 39, 695-697	1
1987	identification of drug candidates against COVID-19. 2020 , 21, 100461	5
1986	Analysing the behaviour of doubling rates in 8 major countries affected by COVID-19 virus. 2020 , 10, 478-483	8
1985	A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases. 2020 , 136, 155228	4
1984	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. 2020 , 10, e044566	4
1983	COVID-19 has no effect on gravity. 2020 , 2, e000046	
1982	The future of sepsis research: time to think differently?. 2020 , 319, L523-L526	1
1981	Remdesivir: First Approval. 2020 , 80, 1355-1363	84
1980	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. 2020 , 7, ofaa319	8
1979	Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients. 2020 , 20, 220	3
1978	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. 2020 , 28, 625-634	12
1977	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. 2020 , 16, 2980-2991	16
1976	The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection. 2020 , 161,	13
1975	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. 2020 , 75, 3373-3378	53
1974	Clinical Experience with COVID-19 at a Specialty Orthopedic Hospital Converted to a Pandemic Overflow Field Hospital. 2020 , 1-7	3
1973	COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. 2020 , 5, 186	40
1972	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. 2020 , 585, 273-276	405

1971	Recommendations for prenatal, intrapartum, and postpartum care during COVID-19 pandemic in India. 2020 , 84, e13336	3
1970	COVID-19-related disease severity in pregnancy. 2020 , 84, e13339	9
1969	A living WHO guideline on drugs for covid-19. 2020 , 370, m3379	275
1968	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. 2020 , 25,	46
1967	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
1966	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. 2020 , 205, 2566-2575	9
1965	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. 2020 , 120, 1680-1690	21
1964	Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. 2020 , 295, 16156-16165	56
1963	Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. 2020 , 17,	2
1962	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. 2020 , 1, 965-975	58
1961	Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19. 2020 , 14, 3803-3813	3
1960	Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. 2020 , 4, 1178	185
1959	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials. 2020 , 288, 198137	25
1958	Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians' Conundrum. 2020 , 56, 119-125	
1957	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. 2020 , 25, 1108-1122	20
1956	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2020 , 17, e1003293	36
1955	Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?. 2020 , 9,	37
1954	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. 2020 , 38, 2405-2415	10

1953 Cardiac Echocardiography in COVID-19 Infection. **2020**, 04, 56-60

1952 Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. **2020**, 21, 32

1951 Remdesivir: an antiviral for the treatment of COVID-19. **2020**, 31, 31-33 1

1950 Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. **2020**, 97, 106145 5

1949 Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial. **2021**, 73, e4012-e4019 12

1948 Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. **2020**, 8, e1249-e1250 18

1947 Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. **2020**, 10, 599-609 3

1946 Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. **2020**, 75, 3359-3365 26

1945 Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019. **2020**, 29, 963689720952089 11

1944 The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. **2020**, 8, 937 10

1943 Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). **2020**, 63, 13205-13227 18

1942 Navigating shifting waters: rapid response to change in the era of COVID-19. **2020**, 50, 786-790 1

1941 Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19). **2020**, 43, 349-368 2

1940 Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay. **2020**, 94, 50

1939 Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report. **2020**, 20, 389 21

1938 Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). **2020**, 15, 1287-1305 52

1937 Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019. **2020**, 11, 1330

1936 [German recommendations for treatment of critically ill patients with COVID-19-version 3 : S1-guideline]. **2020**, 69, 653-664 9

1935	Analysis of clinical features of COVID-19 in cancer patients. 2020 , 59, 1393-1396	2
1934	Remdesivir is Effective for Moderately Severe Patients: A Re-Analysis of the First Double-Blind, Placebo-Controlled, Randomized Trial on Remdesivir for Treatment of Severe COVID-19 Patients Conducted in Wuhan City. 2020 , Volume 12, 15-21	5
1933	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. 2020 , 11, 1818	50
1932	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. 2020 , 2, 100169	68
1931	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China. 2020 , 18, 1559325820949740	
1930	COVID-19 pandemic and the tension between the need to act and the need to know. 2020 , 50, 904-909	4
1929	[COVID-19: epidemiology and clinical facts]. 2020 , 60, 893-898	1
1928	An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. 2020 , 108, 333-336	1
1927	Probiotics and Coronavirus disease 2019: think about the link. 2021 , 126, 1564-1570	10
1926	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. 2020 , 11, 563478	30
1925	Potential protease inhibitors and their combinations to block SARS-CoV-2. 2020 , 1-15	7
1924	How to Be Fair, and Power Research? Select Patients by Flipping a Coin. 2020 , 20, 29-31	1
1923	Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems. 2020 , 13, 1095-1101	7
1922	What Should Be Known by a Urologist About the Medical Management of COVID-19's Patients?. 2020 , 21, 44	
1921	. 2020 , 162, 62	
1920	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. 2020 , 9, 701-705	12
1919	COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review. 2020 , 125, 912-925	15
1918	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. 2020 , 54, 416-437	22

1917	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. 2020 , 11, 572870	50
1916	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. 2020 , 72, 2313-2330	7
1915	Remdesivir, a remedy or a ripple in severe COVID-19?. 2020 , 29, 1195-1198	8
1914	Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. 2020 , 13, 550-563	38
1913	Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. 2020 , 26, 100525	39
1912	[COVID-19 infection-update]. 2020 , 25, 1-8	
1911	The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. 2020 , 25,	4
1910	COVID-19: an update and cardiac involvement. 2020 , 15, 239	7
1909	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. 2020 , 11, 1205	68
1908	The efficacy of colchicine in the management of coronavirus disease 2019: A protocol for systematic review and meta-analysis. 2020 , 99, e21911	7
1907	Directly Acting Antivirals for COVID-19: Where Do We Stand?. 2020 , 11, 1857	10
1906	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131	2
1905	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
1904	A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes. 2020 , 11, 1214	22
1903	Is there any potential management against COVID-19? A systematic review and meta-analysis. 2020 , 28, 765-777	9
1902	Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection. 2020 , 19, 4442-4454	67
1901	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. 2020 , 75, 3366-3372	56
1900	Efficacy of various treatment modalities for nCoV-2019: A systematic review and meta-analysis. 2020 , 50, e13383	12

1899	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. 2020 , 7,	10
1898	Efficacy of Remdesivir in COVID-19. 2020 , 324, 1041-1042	66
1897	Artificial Intelligence-Based Clinical Decision Support for COVID-19-Where Art Thou?. 2020 , 2, 2000104	10
1896	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. 2020 , 8,	61
1895	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. 2020 , 8,	10
1894	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. 2020 , 324, 1048-1057	629
1893	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
1892	Web Exclusive. Annals for Hospitalists Inpatient Notes - Remdesivir-Making Sense of Emerging Evidence. 2020 , 173, HO2-HO3	
1891	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. 2020 , 11, 611275	12
1890	Taming the Autophagy as a Strategy for Treating COVID-19. 2020 , 9,	29
1889	Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?. 2021 , 73, e3990-e3995	18
1888	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. 2020 , 20, 538	17
1887	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. 2020 , 11, 584956	30
1886	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. 2020 , 17,	24
1885	Vaccination Criteria Based on Factors Influencing COVID-19 Diffusion and Mortality. 2020 , 8,	3
1884	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. 2020 , 33, 177-189	0
1883	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. 2020 , 7, 568720	5
1882	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. 2020 , 7, 596587	7

1881	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. 2020 , 11, 6385	62
1880	A rational approach to COVID-19. 2020 , 14, 47	2
1879	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. 2020 , 18, 489	4
1878	COVID-19 and dermatology. 2020 , 50, 1751-1759	18
1877	Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. 2020 , 17,	6
1876	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. 2020 ,	2
1875	The scientific production during 2009 swine flu pandemic and 2019/2020 COVID-19 pandemic. 2020 , 26, 340-345	5
1874	SARS-CoV-2 receptor ACE2 is co-expressed with genes related to transmembrane serine proteases, viral entry, immunity and cellular stress. 2020 , 10, 21415	14
1873	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. 2021 , 19, 877-888	59
1872	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019. 2020 , 2, e0280	20
1871	Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey. 2020 , 6, 28	8
1870	A COVID-19 vaccine-dare to dream. 2020 , 25, 2-7	4
1869	Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. 2020 , 11, 586572	30
1868	Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. 2021 , 12, 717-733	33
1867	COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment. 2020 , 13, 4953-4959	6
1866	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
1865	Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. 2020 , 28, 638-645	18
1864	Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches. 2020 , 1-17	13

1863	Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?. 2020 , 16, 2123-2127	16
1862	Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review. 2020 , 2, 2260-2264	42
1861	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. 2020 , 2020, 9465398	18
1860	COVID-19 and liver disease: An update. 2020 , 43, 472-480	1
1859	A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. 2020 , 86, 104610	13
1858	Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19. 2020 , 30, 1078-1087	44
1857	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. 2020 , 11, 588654	41
1856	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11
1855	Immunotherapeutics for Covid-19 and post vaccination surveillance. 2020 , 10, 527	11
1854	Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats. 2020 , 40, 322-330	9
1853	Targeting the initiation and termination codons of SARS-CoV-2 spike protein as possible therapy against COVID-19: the role of novel harpagide 5-O- β -D-glucopyranoside from P Beauv. (Labiatae). 2020 , 1-14	3
1852	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. 2020 , 65,	29
1851	Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option. 2020 , 8, 1247	2
1850	Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis. 2020 , 8, 591132	33
1849	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. 2020 , 80, 1961-1972	13
1848	News Feature: To counter the pandemic, clinicians bank on repurposed drugs. 2020 , 117, 10616-10620	5
1847	Neurologic complications of COVID-19. 2020 , 38, 1549.e3-1549.e7	110
1846	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. 2020 , 15, 1119-1136	51

1845	Emerging therapies for COVID-19 pneumonia. 2020 , 29, 633-637		10
1844	Pediatric COVID-19: An update on the expanding pandemic. 2020 , 7, 61-63		4
1843	COVID-19: An Update About the Discovery Clinical Trial. 2020 , 13,		8
1842	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. 2020 , 8,		31
1841	Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. <i>Lancet, The</i> , 2020 , 395, 1763-1770	40	1167
1840	The tightrope of science, media and politics. 2020 , 1-2		0
1839	Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19. 2020 , 36, 1131-1135		2
1838	COVID-19 Clinical trials: Quality matters more than quantity. 2020 , 75, 2542-2547		12
1837	Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. 2020 , 9,		5
1836	[Current study results underline cautious commenting]. 2020 , 61, 646		
1835	Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. 2020 , 47, 189-198		15
1834	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. 2020 , 14, 513-517		115
1833	Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. 2020 , 29, 747-754		244
1832	Advances in the relationship between coronavirus infection and cardiovascular diseases. 2020 , 127, 110230		38
1831	Drug repurposing against COVID-19: focus on anticancer agents. 2020 , 39, 86		44
1830	A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. 2020 , 95, 1467-1481		14
1829	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. 2020 , 190, 346-357		8
1828	Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?. 2020 , 11, 791		8

1827	Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis. 2020 , 54, 1236-1255	7
1826	[SARS-CoV-2, COVID-19 and the eye: An update on published data]. 2020 , 43, 642-652	2
1825	Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. 2020 , 24, 940-976	48
1824	Current Perspective of Antiviral Strategies against COVID-19. 2020 , 6, 1624-1634	31
1823	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. 2020 , 324, 460-470	755
1822	Cancer and COVID-19: Unmasking their ties. 2020 , 88, 102041	48
1821	Silencing of immune activation with methotrexate in patients with COVID-19. 2020 , 415, 116942	19
1820	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. 2020 , 12,	129
1819	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. 2020 , 158, 104899	118
1818	What Do We Know About Remdesivir Drug Interactions?. 2020 , 13, 842-844	39
1817	Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. 2020 , 92, 1495-1500	48
1816	Just a little bit more patience□ 2020 , 39, 383-384	1
1815	Remdesivir: A giant step, or a tiptoe?. 2020 , 38, 773-774	0
1814	Immunology of COVID-19: Current State of the Science. 2020 , 52, 910-941	962
1813	Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. 2020 , 43, 645-656	41
1812	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152
1811	COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias. 2020 , 17, 1423-1424	11
1810	[COVID-19: Pathogenesis of a multi-faceted disease]. 2020 , 41, 375-389	12

1809	Synergistic effect of vitamin D and remdesivir can fight COVID-19. 2021 , 39, 4198-4199	17
1808	Covid-19: Selected NHS patients will be treated with remdesivir. 2020 , 369, m2097	11
1807	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). 2020 , 158, 104929	53
1806	A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. 2020 , 60, 954-975	7
1805	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. 2020 , 9, 435-449	35
1804	COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?. 2020 , 29, 964-972	12
1803	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. 2020 , 383, 1827-1837	778
1802	Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis. 2020 , 189, 1218-1226	44
1801	Hospitalized Patients With COVID-19 and Human Immunodeficiency Virus: A Case Series. 2020 , 71, 2021-2022	50
1800	COVID-19 in solid organ transplant recipients: a single-center experience. 2020 , 33, 1099-1105	56
1799	COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. 2020 , 8, 216	84
1798	Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. 2020 , 286, 198057	24
1797	Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. 2020 , 40, 2394-2406	69
1796	Interventions as experiments: Connecting the dots in forecasting and overcoming pandemics, global warming, corruption, civil rights violations, misogyny, income inequality, and guns. 2020 , 117, 212-218	19
1795	Covid-19: a comprehensive review of a formidable foe and the road ahead. 2020 , 14, 869-879	9
1794	COVID-19 and the liver. 2020 , 73, 1231-1240	214
1793	Repurposing cefuroxime for treatment of COVID-19: a scoping review of studies. 2021 , 39, 4547-4554	17
1792	Possible therapeutic agents for COVID-19: a comprehensive review. 2020 , 18, 1005-1020	13

1791	Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. 2020 , 14, 809-814	68
1790	COVID-19 y arritmias: relación y riesgo. 2020 , 27, 153-159	0
1789	Current Status of COVID-19 Therapies and Drug Repositioning Applications. 2020 , 23, 101303	54
1788	The end of social confinement and COVID-19 re-emergence risk. 2020 , 4, 746-755	137
1787	The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19. 2020 , 52, 102473	9
1786	Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. 2020 , 24, 100418	113
1785	The pivotal role of pharmacists during the 2019 coronavirus pandemic. 2020 , 60, e73-e75	9
1784	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. 2020 , 286, 198070	75
1783	Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. 2020 , 11, 1361-136686	
1782	A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. 2020 , 33, 2128-2138	231
1781	Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. 2020 , 71, 3168-3173	56
1780	Novel therapeutic approaches for treatment of COVID-19. 2020 , 98, 789-803	27
1779	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. 2020 , 9, 1397-1406	31
1778	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. 2020 , 100, 1455-1466	75
1777	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. 2020 , 192, E734-E744	51
1776	Implications of COVID-19 in pediatric rheumatology. 2020 , 40, 1193-1213	26
1775	Anakinra for severe forms of COVID-19: a cohort study. 2020 , 2, e393-e400	377
1774	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. 2020 , 29, 973-987	68

1773	Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. 2020 , 69, 1592-1597	69
1772	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. 2020 , 201, 112527	52
1771	Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials. 2020 , 10, e039159	4
1770	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 7, ofaa232	12
1769	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. 2020 , 11, 1606	27
1768	Vaccines and Therapies in Development for SARS-CoV-2 Infections. 2020 , 9,	31
1767	Remdesivir investigational trials in COVID-19: a critical reappraisal. 2020 , 100707	3
1766	Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. 2020 , 20, 5570-5574	159
1765	Rapid advice guidelines for management of children with COVID-19. 2020 , 8, 617	15
1764	Literature-based review of the drugs used for the treatment of COVID-19. 2020 , 10, 100-109	24
1763	Antimicrobial Photodynamic Therapy in the Control of COVID-19. 2020 , 9,	44
1762	Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration. 2020 , 2, 193-196	2
1761	Potential Treatments for SARS-CoV-2 Infection. 2020 , 15, 181-186	4
1760	Use of convalescent plasma in hospitalized patients with COVID-19: case series. 2020 , 136, 759-762	100
1759	COVID-19, five months later. 2020 , 142,	1
1758	Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic. 2020 , 95, 1946-1954	10
1757	The laboratory's role in combating COVID-19. 2020 , 57, 400-414	26
1756	COVID-19: Drug Targets and Potential Treatments. 2020 , 63, 12359-12386	207

1755	COVID-19: from epidemiology to treatment. 2020 , 41, 2092-2112	45
1754	Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. 2020 , 31, 1384-1386	83
1753	Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. 2020 , 38, 100710	6
1752	COVID-19 infection: the China and Italy perspectives. 2020 , 11, 438	49
1751	Additive treatment considerations in COVID-19-The clinician's perspective on extracorporeal adjunctive purification techniques. 2020 , 44, 918-925	14
1750	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov. 2020 , 14, 2159-2164	7
1749	How likely are COVID-19 interventions to benefit the sickest patients?. 2020 , 46, 1441-1444	2
1748	COVID-19 and the heart: An update for clinicians. 2020 , 43, 1216-1222	18
1747	Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. 2020 , 1866, 165878	404
1746	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. 2020 , 182, 744-753.e4	337
1745	Discovering small-molecule therapeutics against SARS-CoV-2. 2020 , 25, 1535-1544	61
1744	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). 2020 , 88, 102063	20
1743	Drug treatment of coronavirus disease 2019 (COVID-19) in China. 2020 , 883, 173326	15
1742	The cytokine storm of COVID-19: a spotlight on prevention and protection. 2020 , 24, 723-730	55
1741	Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness. 2020 , 7, 367	7
1740	Emerging pharmacotherapy for COVID-19. 2020 , 50, 133-137	3
1739	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. 2020 , 9,	14
1738	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. 2020 , 10, 7448-7464	102

1737	Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. 2020 , 14, 971-978	114
1736	GS-5734: a potentially approved drug by FDA against SARS-Cov-2. 2020 , 44, 12417-12429	9
1735	COVID-19 and the Drug Repurposing Tsunami. 2020 , 18, 211-214	9
1734	Remdesivir Bringing Hope for COVID-19 Treatment. 2020 , 88, 29	16
1733	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. 2020 , 146, 285-299	28
1732	[Remdesivir for patients with COVID-19]. 2020 , 61, 869-872	1
1731	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493	59
1730	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. 2020 , 6, 1028-1031	5
1729	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!. 2020 , 10, 610-621	44
1728	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). 2020 , 56, 106080	96
1727	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. 2020 , 64,	26
1726	Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. 2020 , 7,	166
1725	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. 2020 , 9,	29
1724	Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review. 2020 , 12,	27
1723	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. 2020 , 883, 173348	45
1722	Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. 2020 , 52, 584-599	96
1721	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. 2020 , 8, 355	20
1720	COVID-19 Serological Tests: How Well Do They Actually Perform?. 2020 , 10,	72

1719	Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. 2020 , 12, 1565-1578	19
1718	COVID-19 and Advanced Practice Registered Nurses: Frontline Update. 2020 , 16, 551-555	11
1717	The COVID-19 pandemic. 2020 , 57, 365-388	165
1716	Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. 2020 , 10, e039519	59
1715	Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An Analysis. 2020 , 11, 1796	72
1714	Progress in the Research and Development of Anti-COVID-19 Drugs. 2020 , 8, 365	9
1713	SARS-CoV-2 Infektion bei Kindern und Jugendlichen. 2020 , 55, 138-143	
1712	Impact of glycoscience in fighting Covid-19. 2020 , 37, 511-512	5
1711	. 2020 , 162, 20-23	
1710	Successful management of the first reported case in Austria of COVID-19 with ARDS. 2020 , 48, 647-651	7
1709	CED in Zeiten von COVID-19. 2020 , 7, 50-53	
1708	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. 2020 , 114, 102512	39
1707	COVID-19: From pathogenesis models to the first drug trials. 2020 , 13, 1289-1299	1
1706	Commercial influence and covid-19. 2020 , 369, m2456	9
1705	Metabolomics to Predict Antiviral Drug Efficacy in COVID-19. 2020 , 63, 396-398	30
1704	Pharmacotherapies Advice in Guidelines for COVID-19. 2020 , 11, 950	6
1703	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. 2020 , 36, 101791	162
1702	In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies. 2020 , 9, 1523-1533	4

1701	A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. 2020 , 11, 937	109
1700	Emerging Prevention and Treatment Strategies to Control COVID-19. 2020 , 9,	19
1699	Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). 2020 , 56,	42
1698	A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. 2020 , 18, 191	25
1697	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. 2020 , 20, 3140-3148	165
1696	Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndrome. 2020 , 35, 550-553	3
1695	Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas. 2020 , 7, 817-821	6
1694	Case report study of the first five COVID-19 patients treated with remdesivir in France. 2020 , 98, 290-293	19
1693	Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry. 2020 , 9, 1695-1701	4
1692	Dexamethasone in the management of covid -19. 2020 , 370, m2648	124
1691	COVID-19: Progress in diagnostics, therapy and vaccination. 2020 , 10, 7821-7835	77
1690	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919	17
1689	Outbreak of COVID-19: An emerging global pandemic threat. 2020 , 129, 110499	22
1688	Remdesivir for COVID-19: challenges of underpowered studies. <i>Lancet, The</i> , 2020 , 395, 1525-1527	40 55
1687	Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies. 2021 , 17, 1946-1949	56
1686	The COVID-19 pandemic: is our medicine still evidence-based?. 2021 , 190, 11-12	10
1685	A computational prediction of SARS-CoV-2 structural protein inhibitors from (Neem). 2021 , 39, 4111-4121	55
1684	Emerging from the other end: Key measures for a successful COVID-19 lockdown exit strategy and the potential contribution of pharmacists. 2021 , 17, 1950-1953	23

1683	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. 2021 , 45, 100707	92
1682	Remdesivir and tocilizumab: Mix or match. 2021 , 93, 56-58	7
1681	The impact of the SARS-CoV-2 infection, with special reference to the hematological setting. 2021 , 93, 223-233	16
1680	Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. 2021 , 93, 481-490	56
1679	COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. 2021 , 56, 3-11	11
1678	RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. 2021 , 93, 300-310	42
1677	Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. 2021 , 72, 1256-1258	34
1676	A review on drug repurposing applicable to COVID-19. 2021 , 22, 726-741	49
1675	High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. 2021 , 320, L84-L98	9
1674	Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?. 2021 , 76, 335-345	
1673	Treating COVID-19: are we missing out the window of opportunity?. 2021 , 76, 283-285	9
1672	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?. 2021 , 17, 275-284	3
1671	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53	13
1670	Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research. 2021 , 22, 882-895	17
1669	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. 2021 , 93, 775-785	11
1668	SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen. 2021 , 93, 892-898	40
1667	[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. 2021 , 45, 104-121	8
1666	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. 2021 , 27, 112-117	19

1665	Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. 2021 , 766, 145145	29
1664	COVID-19: Between Past and Present. 2021 , 34, 145-157	2
1663	Early prediction of mortality risk among patients with severe COVID-19, using machine learning. 2021 , 49, 1918-1929	44
1662	Operational Recommendations for Scarce Resource Allocation in a Public Health Crisis. 2021 , 159, 1076-1083	7
1661	COVID-19: Discovery, diagnostics and drug development. 2021 , 74, 168-184	133
1660	Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and Entry. 2021 , 7, 1423-1432	8
1659	SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. 2021 , 39, 10-28	5
1658	Remdesivir and its antiviral activity against COVID-19: A systematic review. 2021 , 9, 123-127	77
1657	Detection of SARS-CoV-2 in raw and treated wastewater in Germany - Suitability for COVID-19 surveillance and potential transmission risks. 2021 , 751, 141750	180
1656	Antiviral therapies: advances and perspectives. 2021 , 35, 305-320	10
1655	Perspectives on mechanistic implications of ROS inducers for targeting viral infections. 2021 , 890, 173621	5
1654	Does IHU-Mediterranè Infection influence Gilead Sciences' stock price?. 2021 , 39, 100711	1
1653	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. 2021 , 17, 46-64	209
1652	Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19. 2021 , 77, 435-437	5
1651	Pericarditis secundaria a infecci3n por COVID-19 en un paciente trasplantado renal. 2021 , 41, 349-352	2
1650	System-Wide Strategies Were Associated With Improved Outcome in Critically Ill Patients With Coronavirus Disease 2019: Experience From a Large Health-Care Network. 2021 , 159, 1072-1075	3
1649	Modeling COVID-19 scenarios for the United States. 2021 , 27, 94-105	190
1648	Pathogenesis-directed therapy of 2019 novel coronavirus disease. 2021 , 93, 1320-1342	22

1647	Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. 2021 , 31, e2183	19
1646	Computational Intelligence Methods in COVID-19: Surveillance, Prevention, Prediction and Diagnosis. 2021 ,	
1645	Cardiac Involvement of COVID-19: A Comprehensive Review. 2021 , 361, 14-22	40
1644	Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System. 2021 , 160, 919-921.e3	19
1643	Therapeutic options of TCM for organ injuries associated with COVID-19 and the underlying mechanism. 2021 , 85, 153297	11
1642	COVID 19 and liver: An A-Z literature review. 2021 , 53, 146-152	30
1641	Review on therapeutic targets for COVID-19: insights from cytokine storm. 2021 , 97, 391-398	11
1640	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. 2021 , 41, 303-314	27
1639	[Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]. 2021 , 94, 116.e1-116.e11	12
1638	Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. 2021 , 230, 23-31.e10	65
1637	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. 2021 , 183, 114296	44
1636	Status of Remdesivir: Not Yet Beyond Question!. 2021 , 52, 102-103	0
1635	Nanotechnology for virus treatment. 2021 , 36, 101031	25
1634	Review of registered clinical trials for the treatment of COVID-19. 2021 , 82, 474-493	14
1633	Repurposing medications. 2021 , 19, 336-340	4
1632	Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. 2021 , 384, 497-511	1158
1631	A Large, Simple Trial Leading to Complex Questions. 2021 , 384, 576-577	15
1630	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. 2021 , 14, 95-103	30

1629	SARS-CoV-2: Targeted managements and vaccine development. 2021 , 58, 16-29	21
1628	Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. 2021 , 35, 635-638	16
1627	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426	11
1626	Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?. 2021 , 146, 110452	13
1625	Inclusion complexation of chloroquine with β -CD and γ -cyclodextrin: Theoretical insights from the new B97-3c composite method. 2021 , 1227, 129696	6
1624	Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). 2021 , 174, 229-236	2
1623	Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis. 2021 , 76, 822-825	11
1622	Stem cell therapy in coronavirus disease 2019: current evidence and future potential. 2021 , 23, 471-482	6
1621	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. 2021 , 7,	97
1620	Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells. 2021 , 35, 1127-1129	37
1619	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488	14
1618	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. 2021 , 40, 108-125	24
1617	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891	1
1616	Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein. 2021 , 11, 649-664	14
1615	The place for remdesivir in COVID-19 treatment. 2021 , 21, 20-21	52
1614	Effects of adjunct treatment with intravenous immunoglobulins on the course of severe COVID-19: results from a retrospective cohort study. 2021 , 37, 543-548	10
1613	A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. 2021 , 65,	15
1612	[Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine]. 2021 , 156, 166-171	0

1611	Compassionate use of remdesivir in children with COVID-19. 2021 , 180, 1317-1322	16
1610	Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): A scoping review. 2021 , 41, 101251	14
1609	SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. 2021 , 2, e13-e22	596
1608	Potential inhibitors of SARS-CoV-2: recent advances. 2021 , 29, 349-364	7
1607	A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. 2021 , 185, 104974	11
1606	A Case of COVID-19-Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?. 2021 , 21, 69-72	3
1605	Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. 2021 , 146, 110394	20
1604	Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points. 2021 , 174, 209-220	36
1603	Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib. 2021 , 325, 114765	10
1602	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. 2021 , 17, 11-30	293
1601	COVID19- clinical presentation and therapeutic considerations. 2021 , 538, 125-131	9
1600	Reporting and design of randomized controlled trials for COVID-19: A systematic review. 2021 , 101, 106239	1
1599	Decoding information on COVID-19: Ontological approach towards design possible therapeutics. 2021 , 22, 100486	1
1598	Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials. 2021 , 24, 81-82	4
1597	Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection and in a mouse model expressing human ACE2. 2021 , 66, 925-936	11
1596	Repurposing drugs for the management of COVID-19. 2021 , 31, 295-307	23
1595	A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. 2021 , 34, e14662	15
1594	Risk and Management of Venous Thromboembolism in Patients with COVID-19. 2021 , 73, 78-85	3

1593	Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails. 2021 , 16, 385-397	13
1592	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. 2021 , 4, 206-212	12
1591	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102	7
1590	Compiling Observational Research During a Pandemic: A Necessary Bridge. 2021 , 72, e750-e752	1
1589	Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance. 2021 , 6, 586-593	32
1588	The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions. 2021 , 14, 214-220	10
1587	Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. 2021 , 86, 153440	21
1586	Antibiotic usage and stewardship in patients with COVID-19: too much antibiotic in uncharted waters?. 2021 , 22, 119-125	6
1585	Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians. 2021 , 37, 62-74	3
1584	Selective Pressure-Free Treatments for COVID-19. 2021 , 1, 18-32	2
1583	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231	17
1582	Can drug repurposing strategies be the solution to the COVID-19 crisis?. 2021 , 16, 605-612	10
1581	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. 2021 , 76, 753-757	25
1580	Remdesivir: From Ebola to COVID-19. 2021 , 538, 145-150	18
1579	Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR. 2021 , 100, 106473	2
1578	Lessons from a pandemic: "Should we move towards a more comprehensive nephrology practice?". 2021 , 41, 1-6	1
1577	Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies. 2021 , 56, 90-93	
1576	Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. 2020 , 11, 592908	27

1575	The safety of remdesivir for COVID-19 patients. 2021 , 93, 1910-1912	9
1574	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. 2021 , 10, 89-99	12
1573	[COVID-19 and the kidneys-Clinical aspects]. 2020 , 16, 1-6	
1572	Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). 2021 , 4, 1-13	10
1571	Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. 2021 , 19, 1-15	11
1570	COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic Management of 2019 Novel Coronavirus Disease. 2021 , 44, 128-137	10
1569	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. 2021 , 134, 166-175	7
1568	Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials. 2021 , 93, 1860-1861	7
1567	Coronavirus biology and replication: implications for SARS-CoV-2. 2021 , 19, 155-170	830
1566	Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. 2021 , 71, 138-148	3
1565	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. 2021 , 87, 2170-2185	7
1564	Emerging treatment strategies for COVID-19 infection. 2021 , 21, 167-179	81
1563	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. 2021 , 54, 27-36	8
1562	An enlightening role for cytokine storm in coronavirus infection. 2021 , 222, 108615	19
1561	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
1560	Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. 2021 , 264, 118663	21
1559	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. 2021 , 96, 183-202	30
1558	New spirothiazolidinone derivatives: Synthesis and antiviral evaluation. 2021 , 196, 294-299	1

1557	DGI recommendations for COVID-19 pharmacotherapy. 2021 , 49, 369-370	1
1556	Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries. 2020 , 37, 1-3	2
1555	Cardiology and COVID-19: do we have sufficient information?. 2021 , 17, 705-711	1
1554	Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019. 2021 , 72, 1093-1100	2
1553	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. 2021 , 87, 845-857	3
1552	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. 2021 , 11, 45-52	22
1551	Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. 2021 , 93, 1678-1686	25
1550	Azithromycin in viral infections. 2021 , 31, e2163	36
1549	Pregnancy and COVID-19: pharmacologic considerations. 2021 , 57, 195-203	23
1548	Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view. 2021 , 97, 140-159	19
1547	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. 2021 , 3, 28-40	3
1546	The effect of antivirals on COVID-19: a systematic review. 2021 , 19, 473-486	3
1545	Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. 2021 , 51, 649-656	8
1544	Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection. 2021 , 57, 232-241	67
1543	Emergency Use Authorization for Remdesivir and Its Potential Implications. 2021 , 55, 270-271	2
1542	Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. 2021 , 147, 107-111	68
1541	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. 2021 , 10, 34-48	37
1540	The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials. 2021 , 20, 413-417	1

1539	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects.. 2021 , 31, e2168	14
1538	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287	11
1537	Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis. 2021 , 93, 1171-1174	25
1536	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. 2021 , 25, 13-22	5
1535	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. 2021 , 41, 5-28	43
1534	Lines of Treatment of COVID-19 Infection. 2021 , 91-144	1
1533	Immune response and possible therapeutics in COVID-19.. 2020 , 11, 960-977	2
1532	History and Recent Advances in Coronavirus Discovery. 2021 , 3	2
1531	COVID-19-Directed Medications. 2021 , 171-179	
1530	Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19). 2021 , 9, 163	
1529	COVID-19: What Should the General Practitioner Know?. 2021 , 16, 43-56	4
1528	Available drugs and supplements for rapid deployment for treatment of COVID-19. 2021 , 13, 232-236	1
1527	The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. 2021 , 26, 961-971	2
1526	Application of Nanotechnology in the COVID-19 Pandemic. 2021 , 16, 623-649	40
1525	Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase.	1
1524	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. 2021 , 379, 4	8
1523	A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients. 2021 , 16, e0245025	3
1522	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. 2021 , 1322, 219-260	1

1521	Remdesivir in Children. 2021 , 3, 74-76	
1520	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. 2021 , 21, 3-9	4
1519	Clinical outcomes of COVID-19 in hemodialysis patients in the city of Zonguldak, Turkey. 2021 , 53, 1445-1452	3
1518	QTc Prolongation in COVID-19 Patients Using Chloroquine. 2021 , 21, 314-321	2
1517	Therapeutic options for COVID-19: a quick review. 2021 , 33, 67-84	4
1516	Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. 2021 , 10, 291-304	29
1515	Current treatment in COVID-19 disease: a rapid review. 2021 , 10,	19
1514	Cardiovascular consequences of viral infections: from COVID to other viral diseases. 2021 , 117, 2610-2623	3
1513	A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors. 2021 , 22, 1023-1037	7
1512	RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. 2021 , 1-13	10
1511	ꞤkuꞤkta KoronavirꞤ.ve Somesfobi.	1
1510	Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection. 2021 , 8, 16	10
1509	Net-munity, or the Space between Us ꞤWill Open the Future. 2021 , 47, S104-S109	0
1508	A computational approach for designing novel SARS-CoV-2 Mpro inhibitors: combined QSAR, molecular docking, and molecular dynamics simulation techniques.	4
1507	Transcriptome profiling of different types of human respiratory tract cells infected by SARS-CoV-2 highlight an unique role for inflammatory and interferon response. 2021 , 14, 110-119	0
1506	COVID-19: can we treat the mother without harming her baby?. 2021 , 1-11	2
1505	Caution About Truncation-By-Death in Clinical Trial Statistical Analysis: A Lesson from Remdesivir. 2021 , 3, 538-540	
1504	Relationship between the dynamic changes of serum 2019-nCoV IgM/IgG and patient immunity after 6 month hospital discharge. 2021 , 70, 241-247	3

1503	Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study. 2021 , 90, 107261	11
1502	Emerging therapeutics in the management of COVID-19. 2021 , 10, 1-29	2
1501	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. 2021 , 75, 88-112	14
1500	Dietary Supplements for COVID-19. 2021 , 1318, 499-515	2
1499	Japanese Rapid/Living recommendations on drug management for COVID-19. 2021 , 8, e664	6
1498	Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. 2021 , 35, e14216	14
1497	An overview of the use of biomaterials, nanotechnology, and stem cells for detection and treatment of COVID-19: towards a framework to address future global pandemics. 2021 , 4, 1-16	14
1496	A Longitudinal Cohort Study Using a Modified Child-Pugh Score to Escalate Respiratory Support in COVID-19 Patients - Hubei Province, China, 2020. 2021 , 3, 423-429	1
1495	A review on Coronavirus Disease and potentially active drugs targeting Coronavirus. 2021 , 5, 110	1
1494	Applying the lessons learned from coronavirus disease 2019 to improve pneumonia management. 2021 , 34, 175-179	1
1493	In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response.	1
1492	Two polymorphs of remdesivir: crystal structure, solubility, and pharmacokinetic study. 2021 , 23, 2923-2927	2
1491	Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors. 2021 , 12,	10
1490	COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etkililikleri. 00,	0
1489	Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets. 2021 , 1-14	0
1488	Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. 2021 , 36, 147-153	14
1487	The role of chemical biology in the fight against SARS-CoV-2. 2021 , 478, 157-177	2
1486	Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?. 2021 , 190, 1637-1638	21

1485	Incorporation efficiency and inhibition mechanism of 2'-substituted nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase. 2021 , 23, 20117-20128	3
1484	Clinical characteristics and outcome of novel coronavirus disease in kidney transplant recipients: A single-center prospective observational study. 2021 , 15, 189	
1483	Remdesivir induces persistent mitochondrial and structural damage in human induced pluripotent stem cell derived cardiomyocytes. 2021 ,	2
1482	Identifying COVID-19 cases in outpatient settings. 2021 , 149, e92	0
1481	Structural similarity-based prediction of host factors associated with SARS-CoV-2 infection and pathogenesis. 2021 , 1-12	5
1480	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89	
1479	Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis.	1
1478	Transforming curry extract-spice to liposome-based curcumin: lipocurc to restore and boost brain health in COVID-19 syndrome. 2021 , 271-279	
1477	Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review. 2021 , 11, e042008	1
1476	Lessons from a pandemic: Should we move towards a more comprehensive nephrology practice? 2021 , 41, 1-6	
1475	Transmission, diagnosis, and treatment of coronavirus disease 2020: a review. 381-386	
1474	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. 2021 , 12, 593223	42
1473	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. 2021 , 11, e297	32
1472	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. 2021 , 32, 3-17	3
1471	Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models.	4
1470	Diagnóstico, estabilización y tratamiento del síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2 (SIM-PedS). 2021 , 34, 6-16	
1469	Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis. 2021 , 21, 43-50	5
1468	A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020. 2021 , 18,	18

1467	Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. 2021 , 15, 17534666211007214	6
1466	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. 2021 , 36, e83	10
1465	Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase. 2021 , 7, 164-174	11
1464	A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. 2021 , 11, 2229	9
1463	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. 2021 , 49, e219-e234	119
1462	Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?. 2021 , 25, 3	49
1461	Compliance, Barriers, and Facilitators to Social Distancing Measures for Prevention of Coronavirus Disease 2019 in Northwest Ethiopia, 2020. 2021 , 94, 100632	2
1460	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. 2021 , 13,	7
1459	Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review. 2021 , 14, 13-56	19
1458	Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus. 2021 , 22, 1378-1386	9
1457	Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. 2020 , 11, 621441	14
1456	Applications of digital PCR in COVID-19 pandemic. 2021 , 2, 20200082	8
1455	Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design. 2021 , 12, 13492-13505	0
1454	Characteristics of Clinical Trials Launched Early in the COVID-19 Pandemic in the US and in France. 2021 , 49, 139-151	1
1453	A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients. 2021 , 53, 512-518	1
1452	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,	11
1451	Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. 2020 , 7, 606429	17
1450	[Overview of COVID-19]. 2021 , 58, 65-69	

1449	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. 2021 , 19, 1661-1671	4
1448	Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing. 2021 , 77, 935-937	1
1447	Catalogue of self-targeting nano-medical inventions to accelerate clinical trials. 2021 , 9, 3898-3910	0
1446	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. 2021 , 10, 1227-1240	3
1445	The Immune Response and Effectiveness of COVID-19 Therapies. 2021 , 1321, 115-126	4
1444	Similarities and differences between HIV and SARS-CoV-2. 2021 , 18, 846-851	7
1443	In silico dynamics of COVID-19 phenotypes for optimizing clinical management. 2021 , 118,	14
1442	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. 2021 , 10, 1881-1889	1
1441	Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. 2021 , 4, 100083	20
1440	COVID-19 Infection in Renal Transplant Patients: Early Report From India. 2021 , 31, 271-275	1
1439	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. 2021 , 49, 401-410	26
1438	Antivirals that target the host IMP21-virus interface. 2021 , 49, 281-295	9
1437	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,	28
1436	The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 2021 , 17, e1008470	7
1435	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. 2020 , 11, 605908	37
1434	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. 2021 , 23, 14	93
1433	Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge. 2021 , 1318, 1-22	0
1432	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. 2021 , 100, 116-126	44

1431	Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. 2021 , 65, S41-S46	24
1430	Worsening of heart failure by coronavirus disease 2019 is associated with high mortality. 2021 , 8, 943-952	7
1429	Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective. 2021 , 38, 382-386	1
1428	COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm. 2020 , 10, 599502	3
1427	Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. 2021 , 23, 179-189	9
1426	Colchicine use in patients with COVID-19: a systematic review and meta-analysis.	6
1425	Therapeutic Strategies in the Management of COVID-19. 2020 , 7, 636738	8
1424	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021 , 23, 5	8
1423	Coronavirus disease 2019 management. 2021 , 27, 169-175	1
1422	Microvascular Angiopathic Consequences of COVID-19. 2021 , 8, 636843	8
1421	COVID-19 and Its Implications for Thrombosis and Anticoagulation. 2021 , 42, 316-326	7
1420	The SARS-CoV-2-Inactivating Activity of Hydroxytyrosol-Rich Aqueous Olive Pulp Extract (HIDROX) and Its Use as a Virucidal Cream for Topical Application. 2021 , 13,	12
1419	Atteintes pulmonaires liées à la COVID-19. 2021 , 2, 14-24	0
1418	Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. 2021 , 103, 507-513	13
1417	Development and validation of a prognostic COVID-19 severity assessment (COSA) score and machine learning models for patient triage at a tertiary hospital. 2021 , 19, 56	22
1416	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. 2021 , 39, 747-753	14
1415	Therapeutic opportunities of edible antiviral plants for COVID-19. 2021 , 476, 2345-2364	19
1414	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914	4

1413	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. 2021 , 7, e22483	0
1412	SARS-CoV-2 disinfection in aqueous solution by UV222 from a krypton chlorine excilamp.	2
1411	Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom. 2021 , 36, 1-14	2
1410	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. 2021 , 13,	11
1409	SARS-CoV-2 infection in children. 2020 , 55, 95-102	11
1408	Technological exaptation and crisis management: Evidence from COVID-19 outbreaks. 2021 , 51, 381-392	28
1407	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. 2021 , 24, 102021	18
1406	Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. 2021 , 371, 926-931	117
1405	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. 2021 , 10, 64	5
1404	Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities. 2021 , 21, 42	4
1403	Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. 2021 , 62, 43-48	14
1402	Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. 2021 , 2, 100080	20
1401	SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. 2021 , 9, 620730	22
1400	Remdesivir for COVID-19 in Europe: will it provide value for money?. 2021 , 9, 127-128	8
1399	De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning. 2021 , 15, 8	16
1398	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. 2021 , 101, 106272	30
1397	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. 2021 , 325, 632-644	443
1396	Potential mechanisms of action of convalescent plasma in COVID-19. 2021 , 8, 413-420	5

1395	Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.	3
1394	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. 2021 , 16, 165-183	
1393	Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. 2021 , 78, 568-577	2
1392	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. 2021 , 10, 1945	2
1391	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. 2021 , 8, 604087	
1390	Update in Viral Infections in the Intensive Care Unit. 2021 , 8, 575580	3
1389	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. 2021 , 9, 74-87	
1388	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2021 , 2, CD013587	57
1387	Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study. 2021 , 110, 86-93	12
1386	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). 2021 , 22, 1127-1141	3
1385	Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics. 1-17	3
1384	Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS). 2021 , 94, 116.e1-116.e11	3
1383	Early remdesivir treatment in COVID-19: Why wait another day?. 2021 , 93, 4078-4080	2
1382	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. 2020 , 11, 616595	8
1381	Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. 2021 , 22, 192-201	17
1380	COVID-19-associated liver injury: from bedside to bench. 2021 , 56, 218-230	16
1379	Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region. 2021 , 115, 243-249	3
1378	SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination.	39

1377	Effectiveness of early therapeutic intervention in phases one and two after COVID-19 infection: systematic review. 2021 , 67, 302-312	
1376	In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2.	7
1375	Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection. 2021 , 65, 16-21	6
1374	Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity.	1
1373	General aspects of the COVID-19 pandemic. 2021 , 21, 29-45	1
1372	Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning.	2
1371	Aggregation hot spots in the SARS-CoV-2 proteome may constitute potential therapeutic targets for the suppression of the viral replication and multiplication. 2021 , 12, 1-13	2
1370	Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. 2021 , 26,	3
1369	Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China. 2020 , 11, 615287	4
1368	Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. 2021 , 156, 166-171	1
1367	Mesenchymal stem cell-derived exosomes for organ development and cell-free therapy. 2021 , 2, 1291-1325	1
1366	Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza. 2021 , 45, 535-537	3
1365	The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study. 2021 , 13, 7020-7034	27
1364	Pharmacokinetics of Orally Administered GS-441524 in Dogs. 2021 ,	5
1363	SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets. 2021 , 22, 125	9
1362	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. 2021 , 12, 631139	43
1361	Antiviral optical techniques as a possible novel approach to COVID-19 treatment. 2021 , 14, 2130002	3
1360	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. 2021 , 22, 254-281	17

1359	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. 2021 , 22,	5
1358	Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. 2021 , 16, e0247665	3
1357	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. 2021 , 15, 510	1
1356	Neurological associations of SARS-CoV-2 infection: A Systematic Review. 2021 ,	6
1355	Nanotraps for the containment and clearance of SARS-CoV-2.	1
1354	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. 2021 , 49, 598-622	16
1353	Steroid harms if given early in COVID-19 viraemia. 2021 , 14,	8
1352	Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection. 2021 , 48, 637-650	3
1351	Diagnostic tool or screening programme? Asymptomatic testing for SARS-CoV-2 needs clear goals and protocols. 2021 , 1, 100002	10
1350	Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19. 2021 , 93, 3084-3091	2
1349	Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection. 2021 ,	3
1348	Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations. 2021 , 324, 115134	13
1347	Convalescent Plasma for the Treatment of Severe COVID-19. 2021 , 15, 31-38	4
1346	Prevalence of Foreign Body Aspiration in Children in a Tertiary Care Hospital. 2021 , 59, 111-115	
1345	Beyond Individual Triage: Regional Allocation of Life-Saving Resources such as Ventilators in Public Health Emergencies. 2021 , 29, 263-282	1
1344	Combination anti-coronavirus therapies based on nonlinear mathematical models. 2021 , 31, 023136	
1343	Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. 2021 , 25, 70	5
1342	Remdesivir for the Treatment of COVID-19: A Need for Combined and Studies to Evaluate the Efficacy. 2021 , 34, 343-346	2

1341	Modeling the Effect of Population-Wide Vaccination on the Evolution of COVID-19 Epidemic in Canada.	4
1340	A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy. 2021 , 223, 1538-1543	17
1339	Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis. 2021 , 32, 100743	8
1338	Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study. 2021 , 148, 111966	17
1337	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). 2021 , 27, 115-126	7
1336	Placebo Controls: Now???. 2021 , 69, 9	
1335	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. 2021 , 8, 606755	2
1334	Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients. 2021 , 3, 100057	3
1333	Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies. 2021 , 26,	2
1332	The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication.	3
1331	Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach. 2021 , 10, 815-825	1
1330	Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. 2021 , 894, 173836	22
1329	Optimal control of the SIR model in the presence of transmission and treatment uncertainty. 2021 , 333, 108539	10
1328	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. 2021 , 24, 339-355	1
1327	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. 2021 , 12, 607408	10
1326	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. 2021 , 104, 441-451	10
1325	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
1324	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. 2021 , 414, 115412	7

1323	A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses. 2021 , 24, 102148	6
1322	Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. 2021 , 384, 1015-1027	251
1321	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. 2021 , 593, 418-423	61
1320	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. 2021 , 895, 173890	41
1319	Investigation of structural, treatment and clinical characteristics of COVID-19 along with the challenges caused by its prevalence. 2021 ,	
1318	Impact of remdesivir on 28 day mortality in hospitalized patients with COVID-19: February 2021 Meta-analysis.	1
1317	Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. 2021 , 32, 310-315	13
1316	Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C. 2021 , 76, 1947-1948	1
1315	Remdesivir. 001857872199980	1
1314	Magnesium Treatment on Methylation Changes of Transmembrane Serine Protease 2 (TMPRSS2). 2021 ,	1
1313	COVID-19: A need for new rather than repurposed antiviral drugs.	
1312	The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis.	
1311	COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. 2021 , 50, 357-360	23
1310	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. 2021 , 22, 203	6
1309	Discrete Time Multistate Model With Regime Switching for Modeling COVID-19 Disease Progression and Clinical Outcomes. 1-15	3
1308	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. 10, 64	0
1307	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. 2021 , 11, 6725	12
1306	Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan.	2

1305	Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. 2021 , 109, 829-840	21
1304	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. 2021 , 4, e213071	37
1303	Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. 2021 , 76, 1962-1968	27
1302	Remdesivir for COVID-19: Why Not Dose Higher?. 2021 , 65,	5
1301	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. 2021 , 31, 325-337	29
1300	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. 2021 , 65, 103255	120
1299	SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. 2021 , 13, 361-375	3
1298	Dynamic Monitoring of Ongoing Clinical Trials. 1-12	1
1297	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. 2021 , 104, 671-676	12
1296	A Review of the Progress of COVID-19 Vaccine Development.	1
1295	Current evidence for COVID-19 therapies: a systematic literature review. 2021 , 30,	11
1294	Real-life use of remdesivir in hospitalized patients with COVID-19. 2021 , 34, 136-140	6
1293	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. 2021 , 41, 911-920	2
1292	Identification of guanylyltransferase activity in the SARS-CoV-2 RNA polymerase.	3
1291	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. 2021 , 19, e3001128	25
1290	Virological and serological characterization of critically ill patients with COVID-19 in the UK: a special focus on variant detection.	9
1289	Comparative study on quantum descriptors, molecular docking and dynamic simulation of antiviral drugs with Covid-19. 2021 , 30, 45-51	4
1288	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. 2021 , 17, 1277-1291	1

1287	Niclosamide-Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment. 2021 , 13,	11
1286	Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. 2021 , 34, 473-477	6
1285	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. 2021 , 16, e0247251	14
1284	High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. 2021 ,	5
1283	COVID-19: Potential Repurposing Drugs. 2021 ,	2
1282	A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β a and their combinations.	
1281	Clinical characteristics of older patients with COVID-19: a systematic review of case reports. 2021 , 15, 1-15	3
1280	Knowledge of medical professionals, their practices, and their attitudes toward traditional Chinese medicine for the prevention and treatment of coronavirus disease 2019: A survey in Sichuan, China. 2021 , 16, e0234855	4
1279	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). 2021 , 45, 104-121	1
1278	Telehealth follow up in emergency department patients discharged with COVID-like illness and exertional hypoxia. 2021 , 49, 426-430	4
1277	Making science computable: Developing code systems for statistics, study design, and risk of bias. 2021 , 115, 103685	2
1276	A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 2021 , 11, 198	8
1275	IgA-Dominant Infection-Associated Glomerulonephritis Following SARS-CoV-2 Infection. 2021 , 13,	9
1274	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: Activity against SARS-CoV-2 and Potential Mechanisms. 2021 , 6, 7454-7468	20
1273	Detecting SARS-CoV-2 in the Breath of COVID-19 Patients. 2021 , 8, 604392	10
1272	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2021 , 16, e0248132	20
1271	Coronil, a Tri-Herbal Formulation, Attenuates Spike-Protein-Mediated SARS-CoV-2 Viral Entry into Human Alveolar Epithelial Cells and Pro-Inflammatory Cytokines Production by Inhibiting Spike Protein-ACE-2 Interaction. 2021 , 14, 869-884	11
1270	COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment. 2021 , 104, 426-432	12

1269	Diabetes mellitus in combination with COVID-19: modern views on therapy. 2021 , 8-20	
1268	Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. 2021 , 15, 1213-1223	0
1267	Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2. 2021 , 2, 025024	7
1266	Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. 2021 , 93, 3176-3183	18
1265	Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. 2021 , 110, 1002-1017	5
1264	Remdesivir: An Antiviral Still Seeking a Raison d'être. 2021 , 73, 1857-1859	
1263	Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. 2021 , 12, 635371	21
1262	The effect of azoximer bromide (Polyoxidonium ⁺) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. 2021 , 10,	2
1261	COVID-19 vaccines: The status and perspectives in delivery points of view. 2021 , 170, 1-25	127
1260	Clinical trial preparations for the next pandemic. 2021 , 102, 106292	1
1259	Length of remdesivir treatment in patients with severe COVID-19. 2021 , 17, 200276	1
1258	Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus. 2021 ,	2
1257	Experimental therapies under investigation for COVID-19. 2021 , 11, 187-193	2
1256	The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations. 2021 , 26, 220-239	4
1255	COVID-19 and obesity: what is known about the features of pathogenesis and treatment?. 2021 , 2, 17-23	1
1254	First and second wave of coronavirus-19 disease: A comparative study in patients hospitalized in an ICU of a third-level university hospital. 2021 ,	0
1253	Nowcasting epidemics of novel pathogens: lessons from COVID-19. 2021 , 27, 388-395	11
1252	Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. 2021 , 7, 55	10

1251	Association between thrombocytopenia and 180-day prognosis of COVID-19 patients in intensive care units: A two-center observational study. 2021 , 16, e0248671	12
1250	Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19. 2021 , 13, e13687	
1249	COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. 2021 , 28, 22241-22264	15
1248	The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection. 2021 ,	3
1247	Severe covid-19 pneumonia: pathogenesis and clinical management. 2021 , 372, n436	79
1246	Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?". 2021 , 65,	2
1245	Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?. 2021 , 14, 315-322	2
1244	Human coronaviruses and therapeutic drug discovery. 2021 , 10, 28	5
1243	Precision therapeutic targets for COVID-19. 2021 , 18, 66	15
1242	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. 2021 , 1-14	4
1241	Why Haven't We Found an Effective Treatment for COVID-19?. 2021 , 12, 644850	4
1240	Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV).	2
1239	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. 2021 , 17, 24	7
1238	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. 2021 , 12, 632677	28
1237	Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease. 2021 , 9, 256-264	4
1236	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. 2021 , 76, 1865-1873	3
1235	Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics. 2021 , 13,	11
1234	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. 2021 , 100, e25532	

1233	Perspectives on Drug Repurposing. 2021 , 28, 2085-2099	8
1232	Repositioned Drugs for COVID-19-the Impact on Multiple Organs. 2021 , 3, 1-18	3
1231	Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. 2021 , 53, 559-580	5
1230	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response. 2021 , 76, 1651-1652	
1229	Downregulation of type III interferons in patients with severe COVID-19. 2021 , 93, 4559-4563	10
1228	ACE2 expression is regulated by AhR in SARS-CoV-2-infected macaques. 2021 , 18, 1308-1310	4
1227	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in Kidney transplant patients: A case series and literature review. 2021 , 35, 17	
1226	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. 2021 , 12, 675679	10
1225	Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19. 2021 , 15, 1293-1302	6
1224	Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. 2021 , 10,	10
1223	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. 2021 , 9, 436-446	3
1222	Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference. 2021 , 3,	2
1221	Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Systematic Review of the Literature and Challenges. 2021 , 37, 266-282	5
1220	Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. 2021 , 82, 1124-1130	18
1219	Association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. 2021 , 40, 100812	2
1218	. 2021 , 193, E495-E496	
1217	Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic. 2021 , 77, 156-159	
1216	Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp12/7/8 RNA-dependent RNA Polymerase.	

1215	Aspects About Science in the Context of Production and Communication of Knowledge of COVID-19. 2021 , 30, 1-24	3
1214	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. 2021 , 86, 34-40	39
1213	Nanocarrier vaccines for SARS-CoV-2. 2021 , 171, 215-239	37
1212	Mortality in mechanically ventilated patients with COVID-19: a systematic review. 2021 , 18, 457-471	4
1211	In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. 2021 , 76, 1874-1885	33
1210	Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients. 2021 , 84, 153494	21
1209	Management of COVID-19-associated multisystem inflammatory syndrome in children: A comprehensive literature review. 2021 , 63, 101381	7
1208	Machine learning based on clinical characteristics and chest CT quantitative measurements for prediction of adverse clinical outcomes in hospitalized patients with COVID-19. 2021 , 31, 7925-7935	3
1207	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. 2021 , 22,	10
1206	Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. 2021 , 51, 428-434	5
1205	High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. 2021 , 12, 877-888	28
1204	COVID-19: Antiviral Tedavi.	
1203	Clinical features and risk factors associated with severe COVID-19 patients in China. 2021 , 134, 944-953	3
1202	Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. 2021 , 4, 870-887	4
1201	The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. 2021 , 16, e0249481	13
1200	Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. 2021 , 7, 792-802	24
1199	Rapid clinical evolution for COVID-19 translates into early hospital admission and unfavourable outcome: a preliminary report. 2021 , 16, 744	
1198	Mortality reduction in ICU-admitted COVID-19 patients in Suriname after treatment with convalescent plasma acquired via gravity filtration.	0

1197	Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers. 2021 , 11, 8017	5
1196	Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. 2021 , 4, 2100087	3
1195	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. 2021 , 104, 368504211016936	2
1194	Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study. 2021 , 10, 53	5
1193	Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. 2021 , 897, 173926	33
1192	Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. 2021 , 27, 520-531	164
1191	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. 2021 , 8, ofab153	5
1190	Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. 2021 , 9, 576-586	
1189	Spike Protein Targeting Nano-Glue That Captures and Promotes SARS-CoV-2 Elimination.	0
1188	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
1187	Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19. 2021 , 26,	
1186	Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. 2021 , 105, 598-605	10
1185	Pandemic Perspectives on Medicine and Militarism. 2021 , 11, 252-270	1
1184	Current COVID-19 treatments: Rapid review of the literature. 2021 , 11, 10003	13
1183	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. 2021 , 11, 639108	2
1182	A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. 2021 , 13,	6
1181	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. 2021 , 20, 88	12
1180	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9

1179	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. 2021 , 268, 3961-3968	26
1178	Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies. 2021 , 1230, 129891	13
1177	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. 2021 , 12, 2016	31
1176	Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan. 2021 , 13, e14761	1
1175	COVID-19: Challenges, Preventive Measures and Remediation. 2021 , 37, 285-294	
1174	The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019. 2021 , 1, 52-58	
1173	Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study. 2021 , 19, 1970-1972.e3	5
1172	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). 2021 , 42, 5-18	1
1171	Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?. 2021 , 897, 173928	8
1170	Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study. 2021 , 29, e282-e286	3
1169	Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months. 2021 , 47, 538-548	20
1168	Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. 2021 , 11, 8059	44
1167	Utility of hospitalization for elderly individuals affected by COVID-19. 2021 , 16, e0250730	4
1166	Old Drugs for an Old Pathology? Drug Repurposing for Calcific Aortic Valve Disease. 2021 , 128, 1317-1319	2
1165	Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. 2021 , 16, 546-571	12
1164	The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. 2021 , 12, 633292	1
1163	COVID-19-Associated Pneumonia: Radiobiological Insights. 2021 , 12, 640040	3
1162	Clinical Characteristics and Outcomes of COVID-19 in West Virginia. 2021 , 13,	0

1161	Repurposing of the herbal formulations: molecular docking and molecular dynamics simulation studies to validate the efficacy of phytochemicals against SARS-CoV-2 proteins. 2021 , 1-15	6
1160	COVID-19-associated Cytokine Release Syndrome and Autologous Conditioned Serum: A Hypothesis. 2021 , 000, 000-000	0
1159	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. 2021 , 8, ofab278	8
1158	Year in Review 2020: Noteworthy Literature in Cardiothoracic Critical Care. 2021 , 25, 128-137	0
1157	Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression. 2021 , 12, 691249	6
1156	The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy. 2021 , 53, 1194-1201	5
1155	[Pericarditis secondary to COVID-19 infection in a kidney transplant recipient]. 2021 , 41, 349-352	2
1154	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. 2021 , 9, 522-532	112
1153	COVID-19: breaking down a global health crisis. 2021 , 20, 35	43
1152	Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids. 2021 , 43, 871-885	3
1151	Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths. 2020 ,	0
1150	Observation on China's Strategies to Prevent the Resurgence of the COVID-19 Epidemic. 2021 , 14, 2011-2019	4
1149	Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. 2021 , 154, 104809	2
1148	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. 2021 , 12, 660710	6
1147	Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation. 2021 , 16, e0251910	5
1146	NPC1-regulated dynamic of clathrin-coated pits is essential for viral entry. 2021 , 1	4
1145	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. 2021 , 9,	4
1144	Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. 2021 , 35, e22795	1

1143	Therapeutic strategies to fight COVID-19: Which is the status artis?. 2021 ,	12
1142	Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. 2021 , 174, 663-672	34
1141	Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. 2021 ,	37
1140	Current advances in pharmacological treatments for patients with COVID-19. 2021 , 64, 375-385	
1139	Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates. 2021 , 26,	7
1138	An analysis of inhibition of the severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase by zinc ion: an in silico approach. 2021 , 16, 331-339	3
1137	How COVID-19 has fundamentally changed clinical research in global health. 2021 , 9, e711-e720	20
1136	Pitfalls and perils of survival analysis under incorrect assumptions: the case of COVID-19 data. 2021 , 41, 21-28	1
1135	Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PROACT-COVID study in The Netherlands. 2021 , 9, 813	1
1134	Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland. 2021 , 9, 667507	14
1133	Marine Sponge is a Promising Natural Source of Anti-SARS-CoV-2 Scaffold. 2021 , 12, 666664	5
1132	Antiviral treatment selection for SARS-CoV-2 pneumonia. 2021 , 15, 985-992	1
1131	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. 2021 , 555, 134-139	14
1130	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. 2021 , 10, 1323-1330	9
1129	Overview of SARS-CoV-2 infection in adults living with HIV. 2021 , 8, e294-e305	46
1128	Third force in the treatment of COVID-19: A systematic review and meta-analysis. 2021 , 65, 102218	1
1127	Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study. 2021 , 16, 737	1
1126	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. 2021 , 7, 1001-1008	8

1125	(L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management. 2021 , 12, 623795	21
1124	An overview of ProTide technology and its implications to drug discovery. 2021 , 16, 1149-1161	7
1123	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. 2021 , 1171, 122641	6
1122	What Predicts the Mood of Athletes Involved in Preparations for Tokyo 2020/2021 Olympic Games During the Covid - 19 Pandemic? The Role of Sense of Coherence, Hope for Success and Coping Strategies. 2021 , 20, 421-430	3
1121	Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. 2021 , 116, 1414-1425	12
1120	SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. 2021 , 35, 109055	70
1119	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. 2021 , 14, 601-621	29
1118	Liver and kidney function in patients with Covid-19 treated with remdesivir. 2021 , 87, 4450-4454	7
1117	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. 2021 , 137, 111330	13
1116	identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2. 2021 , 1-16	1
1115	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. 2021 , 9, 2951-2968	4
1114	Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. 2021 , 32, 1-9	3
1113	Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review. 2021 , 10, 143	1
1112	Risks and Benefits of Kidney Transplantation during the COVID-19 Pandemic: Transplant or Not Transplant?. 2021 , 2, 1179-1187	4
1111	Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. 2021 , 87, 4386-4396	1
1110	Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. 2021 , 104, 107851	14
1109	High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions. 2021 , 26, 2439-2444	4
1108	Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV. 2021 , 16, e0251913	6

1107	Therapeutic Agents Against COVID-19 with Clinical Evidence. 2021 , 27, 1608-1617	1
1106	Management of COVID-19: current status and future prospects. 2021 , 23, 104832	6
1105	Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study. 2021 , 10,	3
1104	Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections. 2021 , 14, 655-660	7
1103	Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. 2021 , 53, 691-699	8
1102	Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation. 2021 , 23, e13629	14
1101	Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned. 2021 , 13,	5
1100	Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. 2021 , 8, 645172	1
1099	Current Overviews on COVID-19 Management Strategies. 2021 ,	3
1098	Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. 2021 , 16, e0252057	42
1097	Drug combination therapy for emerging viral diseases. 2021 , 26, 2367-2376	11
1096	Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. 2021 ,	3
1095	Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial.	1
1094	Biomedical Text Link Prediction for Drug Discovery: A Case Study with COVID-19. 2021 , 13,	5
1093	Flavonoids are promising safe therapy against COVID-19. 2021 , 1-22	20
1092	Pregnancy as a risk factor for severe coronavirus disease 2019 using standardized clinical criteria. 2021 , 3, 100319	20
1091	A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. 2021 , 106, 71-77	13
1090	Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. 2021 , 60, 5527-5537	14

1089	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. 2021 , 14,	10
1088	Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. 2021 , 16, e0251170	95
1087	Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). 2021 , 174, 673-679	11
1086	In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection. 2021 , 11, 10271	3
1085	Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study.	3
1084	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. 2021 , 35, 109218	15
1083	NOD: a web server to predict New use of Old Drugs to facilitate drug repurposing. 2021 , 11, 13540	0
1082	Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial. 2021 , 8, 691712	2
1081	Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives. 2021 , 18, 123	3
1080	Gastrointestinal Infection and Liver Injury Are the Risk Factors for Coronavirus Disease 2019 Inpatients With Assisted Ventilation. 2021 , 27, 1348-1354	0
1079	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. 2021 , 22, 75-87	0
1078	The Immunopathobiology of SARS-CoV-2 Infection. 2021 , 45,	1
1077	The impact of SARS-Cov-2 on the Nervous system and Mental Health. 2021 ,	1
1076	Predictive Value of Comorbid Conditions for COVID-19 Mortality. 2021 , 10,	10
1075	Predictors associated with clinical improvement of SARS-CoV-2 pneumonia. 2021 , 27, 857-863	1
1074	Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. 2021 , 16, e0252411	4
1073	Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. 2021 , 12, 680188	0
1072	SARS-CoV-2-Triggered Mast Cell Rapid Degranulation Induces Alveolar Epithelial Inflammation and Lung Injury.	

1071	COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. 2021 , 9, 760-768	1
1070	Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. 2021 , 22, 915	7
1069	A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials. 2021 , 8, 637378	7
1068	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. 2021 , 18, 261-270	2
1067	Mechanism of Inhibition of the Reproduction of SARS-CoV-2 and Viruses by Remdesivir. 2021 , 60, 1869-1875	6
1066	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. 2021 , 23, e31400	2
1065	SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. 2021 , 95, 107493	12
1064	Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. 2021 , 120 Suppl 1, S77-S85	3
1063	Use of Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh: Findings from the First Wave of COVID-19 Pandemic. 2021 , 10,	14
1062	Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.	2
1061	COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review. 2021 , 60, 103071	8
1060	Role of Chest CT in COVID-19. 2021 , 11, 30	2
1059	Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. 2021 , 12, 568789	3
1058	The significance of bioengineered nanoplatfoms against SARS-CoV-2: From detection to genome editing. 2021 , 274, 119289	3
1057	The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. 2021 , 92, 107482	4
1056	Evaluation of Strategies to Fight COVID-19: The French Paradigm. 2021 , 10,	0
1055	5.Confronting COVID-19: Current Issues of SARS-CoV-2 Therapeutic Drug/Vaccine Development. 2021 , 26, 91-97	
1054	Targeting Future Pandemics, a Case for Purine Synthesis and Basic Research. 2021 , 12, 694300	0

1053	Cardiac Arrhythmia Related to Remdesivir in COVID-19. 2021 , 1, 15	
1052	Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. 2021 , 11, 1555-1567	17
1051	COVID-19 in pregnancy: where are we now?. 2021 , 49, 637-642	1
1050	Antimicrobial resistance and COVID-19 syndemic: Impact on public health. 2021 , 15, 124-129	0
1049	Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019. 2021 , 224, 934-937	3
1048	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. 2021 , 1	15
1047	Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective. 2021 , 73, 1754-1764	3
1046	Medication Use Among Patients With COVID-19 in a Large, National Dataset: Cerner Real-World Data 2021 , 43, e173-e196	2
1045	Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. 2021 , 138, 111544	16
1044	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. 2021 , 88, 52-62	4
1043	Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. 2021 , 44, 408-421	12
1042	Science's Response to CoVID-19. 2021 , 16, 2288-2314	2
1041	Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. 2021 , 51, 912-920	9
1040	COVID-19 impact on the liver. 2021 , 9, 3814-3825	6
1039	Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. 2021 , 43, 1007-1019	22
1038	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.	
1037	Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning. 2021 , 4, 673527	4
1036	COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype. 2021 , 18,	

1035	Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19. 2021 , 2, 229-245	2
1034	Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2. 2021 , 138, 111457	11
1033	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. 2021 , 120 Suppl 1, S6-S18	4
1032	Usefulness of Respiratory Mechanics and Laboratory Parameter Trends as Markers of Early Treatment Success in Mechanically Ventilated Severe Coronavirus Disease: A Single-Center Pilot Study. 2021 , 10,	2
1031	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. 2021 , 10, 64	4
1030	Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial. 2021 , 53, 79-79	24
1029	Coping Strategies by University Students in Response to COVID-19: Differences between Community and Clinical Groups. 2021 , 10,	0
1028	Neurological Effects of Sars-Cov-2 And Neurotoxicity of Antiviral Drugs Against Covid-19. 2021 ,	1
1027	He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic Study. 2021 , 12, 700498	4
1026	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study. 2021 , 16, 1037-1046	3
1025	Multi-color super-resolution imaging to study human coronavirus RNA during cellular infection. 2021 ,	
1024	Emergency Department Management of Severe Hypoxemic Respiratory Failure in Adults With COVID-19. 2021 , 60, 729-742	3
1023	Nanotraps for the containment and clearance of SARS-CoV-2. 2021 , 4, 2059-2082	14
1022	Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. 2021 , 11, e048416	14
1021	Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review. 2021 , 14, 2259-2268	5
1020	SARS-CoV-2 and hypertension. 2021 , 9, e14800	4
1019	Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. 2021 , 10, 100096	17
1018	"Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL and PL.". 2021 , 1233, 130094	7

1017	Cu(I)-Catalyzed Click Chemistry in Glycoscience and Their Diverse Applications. 2021 , 121, 7638-7956	49
1016	Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. 2021 , 54, 767-775	9
1015	Crucial mutation in the exoribonuclease domain of nsp14 of PEDV leads to high genetic instability during viral replication. 2021 , 11, 106	0
1014	Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review. 2021 , 13,	2
1013	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study (Preprint).	
1012	Roles and Interplay of SARS-CoV-2 Serology With Clinical Stages of Disease in COVID-19. 2021 , 13, e15953	
1011	Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. 2021 , 28, 3803-3824	7
1010	A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. 2021 , 27, 876-881	10
1009	The scientific community in COVID-19 global pandemic: A systematic update on recent progress and challenges. 2021 , 12, 222-234	
1008	Use of remdesivir in the treatment of coronavirus disease 2019 (COVID-19) infection among Sudanese patients: a case series.. 2021 , 10, 512	
1007	Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer. 2021 , 9,	13
1006	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. 2021 , 1-19	4
1005	A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. 2021 , 27, 917.e1-917.e4	8
1004	SARS-CoV-2 Antiviral Therapy. 2021 , e0010921	12
1003	Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. 2021 , 134, 1920-1929	2
1002	Computational and synthetic biology approaches for the biosynthesis of antiviral and anticancer terpenoids from <i>Bacillus subtilis</i> . 2021 ,	
1001	COVID-19 and gastroenteric manifestations. 2021 , 9, 4990-4997	4
1000	COVID-19 and Kidney Transplantation. 2021 , 2, 288-290	

999	Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia. 2021 , 1	1
998	Integrative management of critical case of Covid 19 with and Modern medicine: A case report. 2021 , 13, 100496-100496	
997	Withdrawal Notice: Nanotechnology-Based Approaches and Investigational Therapeutics against COVID-19. 2021 ,	2
996	Pharmacological Effects of Selected Medicinal Plants and Vitamins Against COVID-19. 2021 , 7,	3
995	Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. 2021 ,	8
994	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. 2021 , 1, 111-128	1
993	Hospital Preparedness and Response Framework during infection pandemic.	
992	Coronavirus Disease 2019 and Liver Transplantation: Lessons from the First Year of the Pandemic. 2021 , 27, 1312-1325	2
991	A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening. 2021 ,	
990	Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management. 2021 , 17, e123120189797	12
989	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. 2021 , 18, e1003660	8
988	[Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia]. 2021 ,	1
987	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase. 2021 , 478, 2425-2443	9
986	Update Alert: Remdesivir for Adults With COVID-19. 2021 , 174, W65	5
985	Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments. 2021 , 12, 716407	12
984	Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. 2021 , 413, 5811-5820	8
983	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? - The Summarising Review. 2021 , 66, 1603975	0
982	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. 2021 , 10,	9

981	Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. 2021 , 118,	44
980	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. 2021 ,	12
979	The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic. 2021 , 35, 203-213	2
978	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). 2021 , 505, 108326	19
977	Recent developments and opportunities in fighting COVID-19. 2021 , 2,	
976	Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings. 2021 , 16, e0255093	3
975	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. 2021 , 19, 1219-1244	3
974	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. 2021 , 11,	6
973	A decision-tree approach to treat platelet hyperactivity and anomalous blood clotting in acute COVID-19 patients.	
972	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. 2021 , 14,	11
971	Pharmacological Treatment for the Management of COVID 19: A Narrative Review. 2021 , 59, 614-621	2
970	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. 2021 , 9,	9
969	Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. 2021 , 1	11
968	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. 2021 , 14,	3
967	Copper-catalysed amination of alkyl iodides enabled by halogen-atom transfer.	15
966	Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. 2021 , 18, 142	6
965	Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations. 2021 , 264, 118011	12
964	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2021 , 10, 1837-1885	10

963	The COVID-19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase-1, and Excessive Hydrolysis Increases Cytotoxicity. 2021 , 5, 1622-1623	2
962	Distinctive features of severe SARS-CoV-2 pneumonia. 2021 , 131,	16
961	Antiviral Effect of Budesonide against SARS-CoV-2. 2021 , 13,	4
960	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. 2021 , 2021, 1-22	0
959	SUMO pathway, blood coagulation and oxidative stress in SARS-CoV-2 infection. 2021 , 26, 100938	6
958	Contemporary narrative review of treatment options for COVID-19. 2021 , 26, 745-767	6
957	Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19.	1
956	Cardiovascular complications of COVID-19. 2021 , 6,	22
955	Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody. 2021 , 125, 7368-7379	6
954	Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. 2021 , 10, 2291-2307	7
953	Liver injury in COVID-19: Known and unknown. 2021 , 9, 4980-4989	1
952	SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. 2021 , 10, 132-150	12
951	What we learned in the past year in managing our COVID-19 patients in intensive care units?. 2021 , 10, 81-101	1
950	Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. 2021 , 11, 700502	6
949	Drug Policies Skyline during COVID-19 Pandemic. 2021 , 10,	0
948	Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study. 2021 , 10,	3
947	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). 2021 , 1	6
946	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. 2021 , 61, 3771-3788	6

945	A retrospective analysis from a single center for 60 COVID-19 patients with asymptomatic, mild to moderate, and severe conditions in Wuxi, China. 2021 , 100, e26748	
944	Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study. 2021 , 61, 3758-3770	10
943	Structural Decoding of a Small Molecular Inhibitor on the Binding of SARS-CoV-2 to the ACE 2 Receptor. 2021 , 125, 8395-8405	1
942	Quantitative Insight into Immunopathology of SARS-CoV-2 Infection. 2021 , 41, 244-257	
941	Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. 2021 , 10, 1907-1931	12
940	Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.	1
939	Evaluation of the 'convalescent plasma therapy' effectiveness and the factors that influence the therapeutic outcome in hospitalized COVID-19 patients: A retrospective cohort study.. 10, 650	
938	Natural product remedies for COVID-19: A focus on safety. 2021 , 139, 386-398	5
937	Complete heart block associated with Remdesivir in COVID-19: a case report. 2021 , 5, ytab200	5
936	Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. 2021 , 37, 100959	31
935	Artificial intelligence for prediction of COVID-19 progression using CT imaging and clinical data. 2022 , 32, 205-212	9
934	Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics. 2021 , 9, 44	6
933	An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. 2021 , 45, 123	1
932	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. 2021 ,	5
931	A Meta-Analysis of Safety of Different Regimens of Remdesivir in COVID-19 Patients. 2021 ,	
930	A review of cardiovascular involvements associated with medications used to treat COVID-19 infection. 2021 , 63, 359-363	
929	Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir.	
928	Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. 2021 , 19, 317-326	5

927	Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. 2021 , 118,	18
926	Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude. 2021 , 12, 1-18	2
925	Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. 2021 , 4, e2114741	28
924	Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. 2021 , 22,	2
923	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. 2021 , 12, 699949	7
922	Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19. 2021 , 22, 214	2
921	Possible response of molecular biotechnology to call SARS-CoV-2. 2021 , 66, 357-369	
920	Kidney implications of SARS-CoV2 infection in children. 2021 , 1	2
919	Remdesivir for the treatment of COVID-19. 2021 , 8, CD014962	22
918	Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. 2021 , 93, 6750-6759	7
917	SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. 2021 , 23, 129	3
916	Drug-Induced Liver Disturbance During the Treatment of COVID-19. 2021 , 12, 719308	4
915	Estimands, Handling of Missing Data and Impact on Assumed Effect Size and Power in Pivotal COVID-19 Treatment Trials. 2021 , 1-22	1
914	Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. 2021 , 1-12	3
913	THE EFFECT OF BARICITINIB USAGE ON THE CLINICAL AND BIOCHEMICAL PROFILES OF COVID-19 PATIENTS- A RETROSPECTIVE OBSERVATIONAL STUDY.	3
912	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. 2021 , 60, 28-45	9
911	Multilevel systems biology analysis of lung transcriptomics data identifies key miRNAs and potential miRNA target genes for SARS-CoV-2 infection. 2021 , 135, 104570	7
910	Assessment of clinical outcomes in renal transplant recipients with COVID-19. 2021 , 93, 6760-6764	1

909	The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. 2021 , 16, e0251378	0
908	Theory and reality of antivirals against SARS-CoV-2. 2021 , 9, 6663-6673	0
907	[Covid-19 in kidney transplantation: Lessons from the French Registry]. 2021 , 17, 233-244	
906	Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data. 2021 , 20, 1559-1564	7
905	Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study. 2021 , 21, 805	3
904	Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology. 2021 , 40, 573-580	5
903	Virtual screening of potential phyto-candidates as therapeutic leads against SARS-CoV-2 infection. 2021 , 4, 100136	2
902	Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. 2021 , 8,	9
901	Experimental and Compassionate Drug Use During the First Wave of the COVID-19 Pandemic: A Retrospective Single-Center Study. 2021 , 38, 5165-5177	0
900	Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase. 2021 , 1-13	2
899	COVID-19 and Effect on Liver Transplant. 2021 , 19, 1-17	0
898	What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis. 2021 , 28, 321-329	0
897	Nasal Swab Performance by Collection Timing, Procedure, and Method of Transport for Patients with SARS-CoV-2. 2021 , 59, e0056921	3
896	Nature-derived hit, lead, and drug-like small molecules: Current status and future aspects against key target proteins of Coronaviruses. 2021 ,	0
895	ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. 2021 , 6, 315	9
894	Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. 2021 , 97, 107702	13
893	AHR signaling is induced by infection with coronaviruses. 2021 , 12, 5148	6
892	Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis. 2021 , 1-12	3

891	Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19. 2021 , 21, 88-90	0
890	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications.	1
889	Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display.	
888	Drug Repurposing for the SARS-CoV-2 Papain-Like Protease. 2021 ,	8
887	Immunological map in COVID-19. 2021 , 54, 547-556	1
886	Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2. 2021 , 541, 736783	2
885	COVID-19: potential therapeutics for pediatric patients. 2021 , 73, 1520-1538	6
884	Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients. 2021 , 13,	2
883	A review of remdesivir for COVID-19 in pregnancy and lactation. 2021 ,	5
882	Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. 2021 , 4,	2
881	Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review. 2021 , 1, 65-76	
880	What is the role of remdesivir in patients with COVID-19?. 2021 , 27, 487-492	5
879	Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study. 2021 , 8, ofab391	1
878	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. 2021 , 13,	2
877	Cardiac arrhythmias in patients presenting with COVID-19 treated in Portuguese hospitals: A national registry from the Portuguese Association of Arrhythmology, Pacing and Electrophysiology. 2021 , 40, 573-580	1
876	Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. 2021 , 59, 799-803	10
875	Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey. 2021 , 38, 4935-4948	2
874	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. 2021 , 2, 100062	9

873	Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of Covid-19 Patients: Scenario So Far. 2021 ,	1
872	Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness. 2021 , 20, 1299-1307	2
871	Applications of Artificial Intelligence, Machine Learning, Big Data and the Internet of Things to the COVID-19 Pandemic: A Scientometric Review Using Text Mining. 2021 , 18,	11
870	Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies. 2021 , 16, e0255622	7
869	Remdesivir in moderate to severe COVID-19: A matter of time?. 2021 , 170, 105711	
868	Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study. 2021 , 22, 1565-1573.e4	2
867	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. 2021 , 10,	4
866	COVID-19, corticosteroids and public health: a reappraisal. 2021 , 197, 48-55	3
865	Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.. 2021 , 4, 215-230	0
864	SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. 2021 , 12, e0233521	11
863	How Informative were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov.	0
862	Semiquantitative ChestCT Severity Score Predicts Failure of Noninvasive Positive-Pressure Ventilation in Patients Hospitalized for COVID-19 Pneumonia. 2021 ,	1
861	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. 2021 ,	66
860	Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles. 2021 ,	5
859	Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020. 2021 , 3, 264-275	2
858	COVID-19 Outbreak Management and Vaccination Strategy in The United States of America. 2021 , 2, 426-453	1
857	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. 2021 , 6, eabd0205	5
856	Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. 2021 , 65, e0111721	7

855	Low rates of venous thromboembolism in hospitalised COVID-19 patients: an Australian experience. 2021 ,	0
854	Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis. 2021 , 61, 4125-4130	3
853	In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals. 2021 , 109, 108038	1
852	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. 2021 , 6, 2305-2315	7
851	Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study. 2021 , 65, e0106321	5
850	Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies. 2021 , 906, 174248	12
849	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. 2021 , 70, 1233-1246	10
848	Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. 2021 ,	8
847	Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. 2021 , 44, 1125-1149	5
846	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. 2021 , 17, e1009929	29
845	The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. 2021 , 302, 198469	11
844	Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. 2021 , 17, e1009898	7
843	Mast cells: Therapeutic targets for COVID-19 and beyond. 2021 , 73, 1278-1292	4
842	In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2. 2021 , 26,	13
841	Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial. 2021 , 224, 1830-1838	6
840	Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. 2021 ,	2
839	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. 2021 , 112, 300-317	4
838	Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. 2021 , 3, 1466-1475	9

837	COVID-19 and Cardiac Arrhythmias: A Review of the Literature. 2021 , 13, e17797	3
836	Interferon β an enhancer of the innate immune response against SARS-CoV-2 infection. 2021 , 158, 105105	2
835	Drug repurposing against coronavirus disease 2019 (COVID-19): A review. 2021 , 11, 683-683	4
834	Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. 2021 , 13, 21866-21902	7
833	Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options. 2021 , 141, 111794	10
832	High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?. 2021 , 22, 828-831	0
831	Potential Effects of Coronaviruses on the Liver: An Update. 2021 , 8, 651658	5
830	Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation. 2021 , 14, 4859-4876	4
829	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. 2021 , 23, 6364-6376	4
828	Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and studies. 2021 , 7, e07962	29
827	Issues in Designing and Interpreting Small Clinical Trials. 2021 , 37, 1332-1339	
826	[Mucociliary clearance in COVID-19 - an underestimated danger area in early phase of disease?]. 2021 , 163, 21-27	1
825	Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. 2022 , 94, 263-271	17
824	Liver disorders in COVID-19, nutritional approaches and the use of phytochemicals. 2021 , 27, 5630-5665	0
823	Predictors of Mortality in COVID-19 Patients in Southern California - Retrospective Multicenter Study. 2021 , 13, e18137	1
822	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. 2021 , 76, 3296-3302	4
821	Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. 2021 , 1-14	2
820	Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis. 2021 , 11, e050532	2

819	Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2). 2021 , 89, 111340	3
818	Network neighbors of viral targets and differentially expressed genes in COVID-19 are drug target candidates. 2021 , 11, 18985	1
817	Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial. 2021 , 8, 696976	4
816	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. 2021 , 9, 729559	7
815	Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers. 2021 , 2, 100421	5
814	Liver injury in COVID-19: A Direct hit or Collateral damage?. 2021 ,	0
813	Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation. 2021 , 1-18	1
812	Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. 2021 , 8, 731436	6
811	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. 2021 , 1, 15	1
810	The role of uncertainty tolerance and meaning in life on depression and anxiety throughout Covid-19 pandemic. 2021 , 179, 110952	10
809	Therapeutic and protective potential of mesenchymal stem cells, pharmaceutical agents and current vaccines against covid-19. 2021 ,	1
808	Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. 2021 , 28, 59570-59593	5
807	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. 2021 , 16, e0256903	0
806	Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients. 2022 , 94, 161-172	4
805	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. 2021 , 13, eabd5524	12
804	A hitchhiker's guide through the COVID-19 galaxy. 2021 , 232, 108849	0
803	Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. 2021 , 14,	5
802	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. 2021 , 11, 734963	0

801	The Cardiac Effects of COVID-19: Review of articles. 2021 , 47, 100981	1
800	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial. 2021 , 174, 1261-1269	33
799	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. 2021 , 1, 252-284	7
798	Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus. 2021 , e00301	5
797	Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. 2021 , 26,	34
796	Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. 2021 , 31, 1212-1214	15
795	Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital. 2021 , 100, e27228	2
794	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. 2021 , 11,	6
793	Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver. 2021 , 65, e0133321	0
792	Mental Health in Affectionate, Antagonistic, and Ambivalent Relationships During the COVID-19 Pandemic: A Latent Profile Analysis. 2021 , 12, 631615	0
791	Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. 2021 , 14, 5597-5606	2
790	Toward Optimal Acute Respiratory Distress Syndrome Outcomes: Recognizing the Syndrome and Identifying Its Causes. 2021 , 37, 733-748	1
789	Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. 2021 , 6, 100274	19
788	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. 2021 , 135, 1076-1090	1
787	Impact of COVID-19 on Pediatric Immunocompromised Patients. 2021 , 68, 1029-1054	6
786	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. 2021 , 115, 105196	1
785	Immunomodulation and immunotherapeutics of COVID-19. 2021 , 231, 108842	2
784	Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection. 2021 , 69, 103309	2

783	Little in vitro effect of remdesivir on mitochondrial respiration and monoamine oxidase activity in isolated mitochondria. 2021 , 350, 143-151	0
782	A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease. 2021 , 21, 5399-5407	
781	Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. 2021 , 107-120	4
780	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. 2021 , 139, 68-79	3
779	Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors. 2021 , 223, 113622	4
778	Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. 2021 , 188, 106602	7
777	Neural connectome prospectively encodes the risk of post-traumatic stress disorder (PTSD) symptom during the COVID-19 pandemic. 2021 , 15, 100378	3
776	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. 2021 , 173, 105848	5
775	The iron(III) and nickel(II) complexes with tetradentate thiosemicarbazones. Synthesis, experimental, theoretical characterization, and antiviral effect against SARS-CoV-2. 2021 , 1246, 131166	5
774	Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors. 2021 , 225, 113789	5
773	Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization. 2021 , 226, 113863	4
772	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. 2021 , 1867, 166264	0
771	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. 2021 , 228, 107931	7
770	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. 2022 , 342-349	0
769	Antiviral effects of black seeds: Effect on COVID-19. 2022 , 387-404	0
768	Severe Acute Respiratory Syndrome Coronavirus 2. 2022 , 231-242	2
767	CSF3 Is a Potential Drug Target for the Treatment of COVID-19. 2020 , 11, 605792	3
766	Can GPR4 Be a Potential Therapeutic Target for COVID-19?. 2020 , 7, 626796	0



765	Integrated gut virome and bacteriome dynamics in COVID-19 patients. 2021 , 13, 1-21	32
764	Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. 2021 , 53, 318-334	10
763	Remdesivir - Current evidence & perspective in management of COVID-19 infection. 2021 , 10, 1808-1813	2
762	Remdesivir for patients with COVID-19. 2021 , 193, E125	1
761	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. 2020 , 11, 582154	17
760	Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open label, Randomised Controlled Trial.	2
759	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. 2021 , 8, ofab040	10
758	Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.	1
757	Analysis of Scientific Publications During the Early Phase of the COVID-19 Pandemic: Topic Modeling Study (Preprint).	
756	Como criar um novo fármaco. 2020 , 8,	
755	Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History. 2020 , 15, 434-436	1
754	A new model for clinical trials to address the COVID-19 emergency. 2020 , 16, 200220	
753	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic (Preprint).	
752	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.	
751	Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. 2020 ,	1
750	Towards the design of multiepitope-based peptide vaccine candidate against SARS-CoV-2.	0
749	Nutritional Considerations in COVID-19 Pandemic. 7,	
748	SARS-CoV-2 infection and some controversies concerning therapy with chloroquine and hidroxychloroquine: case report and selected literature review. 2020 , 74, 348-353	

747	Remdesivir for COVID-19. 2020 , 43, 176-177	0
746	Patients' Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation. 2020 , 1, 100028	
745	Review of current clinical management guidelines for COVID-19 with special reference to India. 2020 , 14, 171-176	3
744	Antiviral treatment for COVID-19: the evidence supporting remdesivir. 2020 , 20, e215-e217	2
743	Comparison of the Clinical Course of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome in 2 Passengers from the Cruise Ship Diamond Princess in February 2020. 2020 , 21, e926835	1
742	Remdesivir for the treatment of COVID-19: A living systematic review.	
741	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. 2021 , 1	1
740	Clinical use of antiviral, antibiotic and immunomodulatory drugs in hospitalized COVID-19 patients: a retrospective study in Bandung, Indonesia. 10, 1091	0
739	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. 2021 ,	3
738	Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. 2021 , 2021, 6741290	2
737	Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. 2021 ,	15
736	[COVID-19: From a clinician's perspective.]. 2020 , 70, 37-44	
735	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. 2020 , 59, 207-225	0
734	Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?. 2021 , 30, 155-159	1
733	Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment. 2020 , 7, 95-102	1
732	COVID-19 Treatment at a Glance. 2020 , 21, 438-445	1
731	SARS-CoV-2: desde sus aspectos genéticos y estructurales hasta su tratamiento. 27, 3	1
730	Potential Antiviral Drug Intervention for Treatment of COVID-19: A Minireview. 2020 , 1, 87-90	

729	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein using mRNA Display.	
728	Current evidence for COVID-19 therapies: a systematic literature review.	
727	Covid-19: The Biggest Threat of the 21 Century: In Respectful Memory of the Warriors All Over the World. 2020 , 21, 409-418	2
726	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. 2020 , 1, 431-438	1
725	Vaccines and Treatment of Coronavirus Disease 2019. 2020 , 95, 364-369	1
724	The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis. 2020 , 2020, 8811798	
723	COVID-19 in Lombardy seven months later: what we learned and modified in patients' management. 2020 , 86, 1353-1354	1
722	A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.	
721	Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials. 2020 , 21, 1028	4
720	Therapy of patients with COVID-19: clinical studies and recommendations in different countries. 2020 , 5-12	1
719	. 2020 , 12, 34-35	
718	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. 2020 , 01,	1
717	Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center. 2021 , 9, 244	
716	Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times. 2020 , 24, 570-574	2
715	FEATURES OF THE USE OF ANTIVIRAL DRUGS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY THE COVID-19 VIRAL INFECTION. 2021 , 3, 14	
714	Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2. 2021 , 10, 94-111	0
713	Approach to geriatric oncology patients during the coronavirus disease 2019 pandemic: A changing treatment paradigm. 2020 , 3, 348	1
712	Tratamiento de COVID-19 en receptores de trasplante renal. 2020 , 9, 173-187	

711	Management of COVID-19: A brief overview of the various treatment strategies. 2020 , 3, 233	1
710	Critical Care for COVID-19 Affected Patients: Updated Position Statement of the Indian Society of Critical Care Medicine. 2020 , 24, S225-S230	2
709	Advances in treatment of COVID-19. 2020 , 1, 1	
708	Remdesivir, the magic bullet for COVID-19?. 2020 , 9, 96	1
707	Intensivists Perspectives on COVID-19. 2020 , 24, 134-136	
706	Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. 2020 , 61, 321-334	1
705	OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. 2020 , 10, 9-20	0
704	Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial.	1
703	Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events. 2021 ,	3
702	COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends. 2021 , 101, 108328	2
701	Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov. 2021 , 22, 788	1
700	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. 2021 , 22,	5
699	Nanotechnology Applications of Flavonoids for Viral Diseases. 2021 , 13,	5
698	Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals. 2021 , e2310	1
697	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. 2021 , 9,	3
696	Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. 2021 , 3, e0566	0
695	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. 2021 ,	4
694	The Impact of COVID-19 on Liver Injury: COVID-19 and Liver Injury. 2021 ,	3

- 693 Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir. **2020**, 6, e19538 o
- 692 COVID-19: An Update Regarding the Quest for Finding an Effective Cure. **2020**, 12, e9010
- 691 Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients.
- 690 Identification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. 1
- 689 Rationale and prognosis of repurposed drugs with risk stratification of COVID-19 patients requiring Oxygen supplementation: A systematic review and meta-analysis.
- 688 Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytotoxicity-associated false positives.
- 687 A comparison of Remdesivir versus Au22Glutathione18 in COVID-19 golden hamsters: a better therapeutic outcome of gold compound.
- 686 Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies. **2020**, 130, 5622-5623 o
- 685 Strategies and Challenges to Develop Therapeutic Candidates against COVID-19 Pandemic. **2020**, 14, 16-21 4
- 684 Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. **2020**, 8, 383-399
- 683 COVID-19 Therapeutics: Making Sense of It All. **2020**, 31, 239-249
- 682 SARS-CoV-2 specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking and large-scale production for Adoptive Cell Therapy.
- 681 Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens.
- 680 Schlaganfall und COVID-19. **2020**, 39, 626-628
- 679 Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry.
- 678 The Intensive Care Unit in the "COVID-19 Era" **2020**, 4, 075-078
- 677 Differences and similarities in diagnostic methods and treatments for Coronavirus disease 2019 (COVID-19): a scoping review.
- 676 Transcriptome Profiling of different types of human respiratory tract cells infected by SARS-CoV-2 Highlight an unique Role for Inflammatory and Interferon Response.

- 675 Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysis.
- 674 Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients. 1
- 673 Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining methodological quality.
- 672 Comparative effectiveness and safety of antiviral agents for patients with COVID-19: Protocol for a systematic review and individual-patient data network meta-analysis. **2020**, 15, e0241947 0
- 671  COVID-19 
- 670 An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic. **2020**, 3, 309-321
- 669 Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors. **2020**, 26, S63-S77 2
- 668 Analysis of Structure, Mechanism of Action and Efficacy of Potential and Ideal COVID-19 Treatments. **2020**, 1, 197-208
- 667 Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. **2020**, 2, 100224 0
- 666 New insights on potential therapeutic options and vaccines for corona virus disease-2019. **2021**, 32, 67-74
- 665 Identifying COVID-19 cases in primary care settings.
- 664 Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19. 2
- 663 Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses.
- 662 Pentoxifylline and Covid-19: A Systematic Review. 1
- 661 Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol. **2020**, 8, 1527 2
- 660 BET 1: The role of remdesivir in COVID-19 infection. **2020**, 37, 522-523
- 659 Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?. **2020**, 24, 10228-10238 4
- 658 Hospital emergency management plan during 2019 novel coronavirus (SARS-CoV-2) pandemic in non-epidemic areas. **2020**, 13, 2753-2757

657	Therapeutic strategies against COVID-19. 2020 , 91, e2020038	2
656	The "perfect" storm: Current evidence on pediatric inflammatory multisystem disease during SARS-CoV-2 pandemic. 2020 , 91, e2020034	2
655	Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease. 2020 , 10, 4538-4546	10
654	Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. 2021 , 37, 9-17	1
653	Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. 2020 , 91, e2020102	8
652	Cardiac injury is independently associated with mortality irrespective of comorbidity in hospitalized patients with coronavirus disease 2019. 2020 , 27, 472-473	1
651	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. 2021 , 153, 7-16	4
650	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. 2021 , 13, 163-171	1
649	Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview. 2021 , 92, e2021317	1
648	Tackling COVID-19 Using Small-Molecule Drugs. 2022 , 73-84	
647	Treatment and therapeutic agents. 2022 , 121-176	
646	Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. 2021 , 351, 109744	0
645	Real-time ultra-sensitive detection of SARS-CoV-2 by quasi-freestanding epitaxial graphene-based biosensor. 2022 , 197, 113803	4
644	Evaluation of role of remdesivir in covid-19 patients outcome: A retrospective analysis. 2021 , 8, 5-9	
643	Pharmacoeconomic Analysis of Treatment Regimens for Coronavirus Infection Coronavirus Disease-19. 2021 , 9, 1182-1189	0
642	Antiviral drugs suppress infection of 2019-nCoV spike pseudotyped virus by interacting with ACE2 protein. 2021 , e22948	1
641	The Effect of Remdesivir in Patients with Severe COVID-19, Reporting Case Series. 2021 , In Press,	
640	A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. 2021 , e2103240	3

639	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. 2021 , 12, 704205	13
638	Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. 2021 , 29, 449-467	2
637	Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease. 2021 , 22,	2
636	Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital.. 2021 , 13, e19487	0
635	Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. 2021 , 14, 8557-8571	9
634	On Speeding Up and The Lunar Mare.. 2022 , 12, 10-12	
633	Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo.	
632	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. 2021 ,	16
631	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. 2021 , 22, 304	0
630	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. 2021 , 2021, 4078713	1
629	Application of the Pluripotent Stem Cells and Genomics in Cardiovascular Research-What We Have Learnt and Not Learnt until Now. 2021 , 10,	1
628	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. 2021 , 1-6	
627	Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. 2021 , 19, 391	2
626	A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2. 2021 , 1-10	2
625	Current status of therapeutic approaches and vaccines for SARS-CoV-2. 2021 ,	2
624	Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations. 2021 ,	1
623	Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India.. 2021 , 13, e19976	0
622	Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city. 2021 ,	0

621	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. 2021 , 10, 1-32	0
620	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. 2021 , 40, 6235-6242	1
619	Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction. 2021 ,	3
618	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. 2021 , JVI0155121	8
617	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. 2021 , 71, 39	3
616	Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2. 2021 , 1-7	
615	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. 2021 , 12, 732403	2
614	COVID-19 Pandemic Between Severity Facts and Prophylaxis. 2021 , 16, 1934578X2110412	1
613	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
612	Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. 2021 , 22,	15
611	Exploration of SARS-CoV-2 3CL Inhibitors by Virtual Screening Methods, FRET Detection, and CPE Assay. 2021 ,	1
610	Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic.. 2021 , 10,	1
609	Learning for the next pandemic: the Wuhan experience of managing critically ill people. 2021 , 375, e066090	0
608	The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study.. 2021 , 95, 153868	0
607	Anti-SARS-CoV-2 Inhibitory Profile of New Quinoline Compounds in Cell Culture-Based Infection Models. 2021 ,	2
606	Case Report: Severe SARS-CoV-2 Infection with Remdesivir in a Patient with ESRD. 2021 ,	0
605	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. 2020 , 153,	2
604	Recent Advances on Drugs and Vaccines for COVID-19. 2021 , 58, 469580211055630	1

603	Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). 2021 , 8, e706	4
602	MOTIVATIVE POTENTIAL OF A TEENAGEER DURING DISTANCE LEARNING. 2021 , 2, 91-98	
601	Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center.. 2021 , 10, 4236-4241	0
600	Using sequence clustering to identify clinically relevant subphenotypes in patients with COVID-19 admitted to the intensive care unit.. 2022 , 29, 489-499	
599	Novel infectious causes of acute pancreatitis: A comprehensive review. 2021 , 7, 83	
598	COVID-19 in hemodialysis patients: Experience from a Western Indian center. 2021 ,	0
597	Covid-19: New Use of Therapeutics. 2021 , 299-313	
596	Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. 2021 , 37, e00077721	2
595	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. 2021 , 319, 01035	
594	ADENet: a novel network-based inference method for prediction of drug adverse events.. 2022 ,	
593	Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment. 2022 , 000, 000-000	1
592	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.. 2022 , 1	0
591	Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics.. 2022 , 1-17	0
590	Psychological maltreatment, coping flexibility, and death obsession during the COVID-19 pandemic: A multi-mediation analysis.. 2022 , 1-9	1
589	Non-significant Trends in COVID-19 Trials: Is There a Significance?. 2021 ,	1
588	Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.. 2022 , 5,	6
587	RdRp inhibitors and COVID-19: Is molnupiravir a good option?. 2021 , 146, 112517	11
586	Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study.. 2022 , 7, 109-121	1

- 585 Pensamiento complejo en la educación médica: un reto ineludible ante la pandemia de COVID-19. **2020**, 87-95
- 584 Clinical effectiveness and safety of sofosbuvir/velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial. **2021**, 10, 294
- 583 Does Remdesivir maintain the race in the general treatment protocol of COVID-19?. **2021**, 10, 4621-4622
- 582 Characterisation of current pharmacotherapeutic COVID-19 clinical trials in India: A registry-based descriptive analysis. **2021**, 65, 141-145
- 581 Establishment of a quantitative RT-PCR detection of SARS-CoV-2 virus.. **2021**, 26, 147 0
- 580 A review of COVID-19 therapeutics in pregnancy and lactation. 1753495X2110562 2
- 579 Impact of COVID-19 in Hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.. **2022**, 0
- 578 A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.. **2022**, e2100382 1
- 577 Potential therapeutic options for COVID-19: an update on current evidence.. **2022**, 27, 6 13
- 576 The Goldilocks Time for Remdesivir - Is Any Indication Just Right?. **2021**, 3
- 575 An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives. 0
- 574 Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients.. **2022**, 11, 0
- 573 High-cited favorable studies for COVID-19 treatments ineffective in large trials.
- 572 DrugDevCovid19: An Atlas of Anti-COVID-19 Compounds Derived by Computer-Aided Drug Design.. **2022**, 27, 0
- 571 COVID-19: les thérapeutiques. **2022**, 1, 13-13
- 570 A Retrospective Study on Experience of High-flow Nasal Cannula Oxygen in Critically Ill COVID-19 Adult Patients Admitted to Intensive Care Unit.. **2022**, 26, 62-66 0
- 569 Adverse Effects of COVID-19 Treatments: A Special Focus on Susceptible Populations. **2022**,
- 568 Antiviral Drugs and Their Roles in the Treatment of Coronavirus Infection. 0

567	Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19.. 2022,	9
566	Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice.. 2022, 7,	4
565	Immune-guided therapy of COVID-19.. 2022,	2
564	Tafenoquine and its derivatives as inhibitors for the Severe Acute Respiratory Syndrome Coronavirus 2.. 2022, 101658	1
563	Strategies for drug repurposing against coronavirus targets.. 2022, 3, 100072	1
562	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.. 2022, 18, 459-472	7
561	Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis.	2
560	Pulmonary Aspects of COVID-19.. 2022, 73, 81-93	2
559	Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality.. 2022, 1	10
558	Identification of Bioactive Components in QingFeiPaiDu Decoction for Treatment of COVID-19 by Network Pharmacology. 2022, 000, 000-000	
557	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening.. 2022, 5, 8-19	0
556	Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission.. 2022, 12, 640	2
555	The discovery of herbal drugs and natural compounds as inhibitors of SARS-CoV-2 infection in vitro.. 2022, 76, 402	2
554	The CO Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro.. 2022, 14,	0
553	How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov.. 2022, 17, e0262114	0
552	Better COVID-19 Intensive Care Unit survival in females, independent of age, disease severity, comorbidities, and treatment.. 2022, 12, 734	1
551	Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2.. 2022, 50, 6	2
550	Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19-A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan.. 2022, 58,	0

549	COVID-19: Gastrointestinal manifestations, liver injury and recommendations.. 2022 , 10, 1140-1163	1
548	Prospectus of Advanced Nanomaterials for Antiviral Properties..	2
547	Therapeutic potential of pyrrole and pyrrolidine analogs: an update.. 2022 , 1	9
546	Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.. 2022 , 22, 107	7
545	Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.. 2022 ,	2
544	[Antiviral drugs : Potent agents, promising therapies for COVID-19 and therapeutic limitations].. 2022 , 63, 118	
543	Repurposing of Mycobacterium indicus pranii for the severe form of COVID -19 patients in India: A cohort study.. 2021 ,	4
542	Spontaneous Complete Remission of Acute Myeloid Leukemia in the Absence of Disease-Modifying Therapy following Severe Pulmonary Involvement by Coronavirus Infectious Disease-19.. 2022 , 2022, 2603607	1
541	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein.. 2022 , 28, 37	
540	Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.. 2022 , 14,	2
539	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.. 2022 ,	23
538	Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial.. 2022 , 43, 101242	5
537	Cytopathic Effect Assay and Plaque Assay to Evaluate Activity of Antiviral Compounds Against Human Coronaviruses 229E, OC43, and NL63.. 2022 , 12, e4314	0
536	Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: a retrospective case-control study.. 2022 ,	2
535	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).. 2022 , 8,	1
534	Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.. 2022 ,	5
533	Strategies for fighting pandemic virus infections: Integration of virology and drug delivery.. 2022 ,	2
532	Multi-color super-resolution imaging to study human coronavirus RNA during cellular infection.. 2022 , 100170	2

531	Benefits from Shortening Viral Shedding by Traditional Chinese Medicine Treatment for Moderate COVID-19: An Observational Study.. 2022 , 2022, 7179050	
530	Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.. 2022 , e0304421	1
529	Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis.. 2022 , 9, 808221	0
528	Reply letter to: Correspondence on 'Coronavirus disease 2019 in patients with cardiovascular disease' (J Cardiovasc Med (Hagerstown). 2022 Jan 1;23(1):e42. doi: 10.2459/JCM.0000000000001276. PMID: 34874340).. 2022 , 23, 205	0
527	High-Dose Convalescent Plasma for Treatment of Severe COVID-19.. 2022 , 28,	7
526	Seaweeds as potential source of bioactive compounds with special emphasis on bioprospecting in COVID-19 situation. 2022 , 455-469	
525	Efficacy of awake prone positioning for severe illness coronavirus disease 2019 patients: a propensity score-adjusted cohort study.. 2022 , 9, e734	0
524	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.. 2022 ,	2
523	Treatment Options in CoViD19. 2022 , 63-94	
522	Accelerating the discovery of the beyond rule of five compounds that have high affinities toward SARS-CoV-2 spike RBD.. 2022 , 1-10	
521	The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country.. 2022 , 5, 100107	
520	Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricu Oncology Institute series.. 2022 , 7, 100423	1
519	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. 2022 , 58,	0
518	Therapeutics for COVID-19 and post COVID-19 complications: An update.. 2022 , 3, 100086	13
517	PHARMACOLOGIC TREATMENT AND MANAGEMENT OF COVID-19. 2022 ,	
516	Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population.. 2022 , 17, e0255495	0
515	Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.. 2022 , 147, 112700	7
514	AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India.. 2022 , 66, 102814	3

513	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. 2021 , 23, 28	2
512	Azvadine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. 2021 , 6, 414	6
511	The race for a COVID-19 vaccine: where are we up to?. 2021 , 1-22	2
510	A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological Interventions.	2
509	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline.. 2021 , 30,	3
508	A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19.. 2021 , 12, 794382	6
507	Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients.. 2021 , 11,	3
506	Pharmacological treatment of COVID-19: an opinion paper. 2021 ,	10
505	Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data. 2020 ,	
504	Procuring Covid-19 Vaccine and the Contemporary Geopolitical Paradigm for Bangladesh. 2021 , 5, 118-126	
503	Possible Therapeutic Intervention Strategies for COVID-19 by Manipulating the Cellular Proteostasis Network.. 2021 , 1352, 125-147	0
502	Outbreak of COVID-19: A Detailed Overview and Its Consequences.. 2021 , 1353, 23-45	3
501	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2.. 2022 , 13, 3826-3836	2
500	Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club.. 2022 , 74, S244-S250	3
499	Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review.. 2022 , 7, e5-e23	0
498	Internal Medicine, Infection Control, and Occupational Health Services. 2022 , 37-52	
497	COVID-19 and lung involvement. 2022 , 189-211	
496	Remdesivir: Mechanism of Metabolic Conversion from Prodrug to Drug.. 2021 ,	0

495	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. 2022 , 11,	4
494	Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2.. 2022 , 1-15	
493	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. 2022 , e13763	1
492	Remdesivir and Human Milk: A Case Study.. 2022 , 8903344221076539	0
491	An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library.. 2022 , 10, 816576	1
490	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.. 2022 , 27, 13596535221082773	0
489	A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales.. 2022 ,	1
488	Emerging small molecule antivirals may fit neatly into COVID-19 treatment.. 2022 , 38, 1-15	1
487	Guidance for the pharmacological management of COVID-19 in the emergency setting.. 2022 , 1-4	1
486	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets.. 2022 , 23,	1
485	COVID-19 in dialysis: clinical impact, immune response, prevention and treatment.. 2022 ,	9
484	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.. 2022 , 14,	3
483	Non-productive exposure of PBMCs to SARS-CoV-2 induces cell-intrinsic innate immunity responses.	0
482	Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect.. 2022 , 1-19	0
481	Efficacy of repurposed antiviral drugs: Lessons from COVID-19.. 2022 ,	2
480	Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis.. 2022 , 48, e20210393	3
479	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.. 2022 , 79, 142	1
478	COVID-19 can be called a treatable disease only after we have antivirals.. 2022 , 67, 999-999	0

477	Rapid Response in an Uncertain Environment: Study of COVID-19 Scientific Research Under the Parallel Model.. 2022 , 15, 339-349	
476	Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.. 2022 , 17, e0262564	1
475	Application of nucleoside or nucleotide analogues in RNA dynamics and RNA-binding protein analysis.. 2022 , e1722	1
474	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.. 2022 , 10,	2
473	Efficacy and Safety of a Phytopharmaceutical Drug Derived from <i>Cocculus hirsutus</i> in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial.. 2022 , 11, 807	0
472	What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?. 2022 , 13, 843587	0
471	Synthesis of chiral sulfinic acid esters by asymmetric condensation.. 2022 ,	10
470	Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.. 2022 , 10,	2
469	First and second wave of coronavirus-19 disease: A comparative study in patients hospitalized in an ICU of a third-level university hospital.. 2021 , 46, 166-166	0
468	Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study.. 2022 , 42, 345	0
467	Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.. 2022 , 13, 124	0
466	Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in Silico Approach.. 2022 , 27,	0
465	SARS-CoV-2 vaccines: Clinical endpoints and psychological perspectives: A literature review.. 2022 , 15, 515-525	1
464	Therapeutic strategies for COVID-19 patients: An update.. 2022 ,	
463	Hydrogen-oxygen therapy alleviates clinical symptoms in twelve patients hospitalized with COVID-19: A retrospective study of medical records.. 2022 , 101, e27759	0
462	Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial.. 2022 , 12, e057024	0
461	How Is Mass Spectrometry Tackling the COVID-19 Pandemic?. 2022 , 2,	0
460	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis.	

459	Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS.. 2022 , 13, 692828	3
458	Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2.. 2022 , 15,	0
457	Real World Impact of Remdesivir and Dexamethasone on Clinical Outcomes of Severe Coronavirus Disease 2019 in a Community Hospital.. 2022 ,	1
456	Phosphoramidate Prodrugs Continue to Deliver: The Journey of Remdesivir (GS-5734) from the Liver to Peripheral Blood Mononuclear Cells.. 2022 , 13, 520-523	
455	Viable SARS-CoV-2 Shedding Under Remdesivir and Dexamethasone Treatment.. 2022 ,	0
454	Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series. 10, 512	1
453	Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS-CoV-2.. 2022 , 14,	1
452	Evaluation of Natural Peptides to Prevent and Reduce the Novel SARS-CoV-2 Infection. 2022 , 2022, 1-13	0
451	Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 .. 2022 , 13, 721103	1
450	Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M) as Potential COVID-19 Therapies.. 2022 , 9, 781039	1
449	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters.. 2022 , e0370521	1
448	Selenium in the Prevention of SARS-CoV-2 and Other Viruses.. 2022 , 1	3
447	Predictors of Quality of Life in Patients with Alopecia Areata.. 2022 ,	1
446	Small hospitals in battle against COVID-19: A single-center cohort study. 2022 , 35, 1-5	
445	Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.. 2022 , 16, 827-841	1
444	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.. 2022 , 12, e048502	3
443	A look back at the first wave of COVID-19 in China: A systematic review and meta-analysis of mortality and health care resource use among severe or critical patients.. 2022 , 17, e0265117	2
442	Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.. 2022 ,	7

441	Therapeutic Strategies for COVID-19 Lung Disease in Children.. 2022 , 10, 829521	0
440	RK-33, a small molecule inhibitor of host RNA helicase DDX3, suppresses multiple variants of SARS-CoV-2.. 2022 ,	1
439	Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial.	
438	Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study.. 2022 , 12, 5323	3
437	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. 2022 , 1,	0
436	Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.. 2022 , 13, 844749	1
435	Geospatial evaluation of COVID-19 mortality: Influence of socio-economic status and underlying health conditions in contiguous USA.. 2022 , 141, 102671	1
434	SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells.. 2022 , 11,	0
433	Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial.. 2022 , 13, 690726	1
432	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. 2022 ,	1
431	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.. 2022 , 13, 834942	2
430	Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2.. 2022 , 105512	0
429	Molnupiravir and Its Antiviral Activity Against COVID-19.. 2022 , 13, 855496	10
428	Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis.. 2021 ,	1
427	Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect.. 2022 , 1	1
426	SARS-CoV-2 Pandemic Tracing in Italy Highlights Lineages with Mutational Burden in Growing Subsets.. 2022 , 23,	1
425	Production of carrier/antioxidant particles by Supercritical Assisted Atomization as an adjuvant treatment of the CoVID-19 pathology.. 2022 , 186, 105604	0
424	Dynamic Changes in Breast Milk Microbiome in the Early Postpartum Period of Kenyan Women Living with HIV Are Influenced by Antibiotics but Not Antiretrovirals.. 2022 , e0208021	

423	Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.. 2022 , 58,	2
422	Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan.. 2022 ,	3
421	Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2.. 2022 , 235, 114295	1
420	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. 2022 , 179, 106201	3
419	Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.. 2022 ,	2
418	Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.. 2022 ,	0
417	A comparison of Remdesivir versus gold cluster in COVID-19 animal model: A better therapeutic outcome of gold cluster.. 2022 , 44, 101468	0
416	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. 2021 , 1, 216-234	0
415	The <i>Petasites hybridus</i> CO ₂ -extract (Ze 339) blocks SARS-CoV-2 replication in vitro.	
414	Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M, Impairing Variants Replication In Vitro and In Vivo.. 2021 , 15,	5
413	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. 2021 , 13, 1850-1874	1
412	A sequential test to compare the real-time fatality rates of a disease among multiple groups with an application to COVID-19 data. 2021 , 9622802211061927	0
411	Review on Adverse effects or side effects of Remdisivir. 2021 , 162-166	
410	Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: A single center study.. 2022 , 38, 405-410	0
409	Clinical trials during the COVID-19 pandemic: research design and lessons. 2021 , 214-231	
408	Recent insights into COVID-19 in children and clinical recommendations. 2021 ,	2
407	Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenza: study protocol for a randomized parallel placebo-controlled double-blind multicenter trial.. 2021 , 22, 955	1
406	SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury.. 2021 , 6, 428	9

405	Incidence and severity of SARS-CoV-2 infection in HIV-infected individuals during the first year of the pandemic.. 2021,	0
404	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021,	3
403	Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity.	2
402	COVID-19: management in the ICU. 2021, 124-143	1
401	Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges.. 2021,	6
400	Real-World Effectiveness Of Remdesivir In Adults Hospitalized With Covid-19: A Retrospective, Multicenter Comparative Effectiveness Study.. 2021,	3
399	Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment.. 2022, 28, 3-11	0
398	Current strategies in diagnostics and therapeutics against novel coronavirus disease (COVID-19). 2022, 72, 171-197	0
397	Temporal trends in hospitalizations and 30-day mortality in older patients during the COVID pandemic from March 2020 to July 2021.	
396	Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences.. 2021, 9, 802766	3
395	Recapitulating Trafficking of Nucleosides Into the Active Site of Polymerases of RNA Viruses: The Challenge and the Prize.. 2021, 3, 705875	
394	In Silico Study of Pubchem Compounds for Solanum torvum as Antiviral Agent against SARS-CoV-2. 2021, 1, 235-242	
393	Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study.. 2021, 14, 5287-5291	1
392	Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.	
391	Introduction. 2021, v-vii	
390	Major Publications in the Critical Care Pharmacotherapy Literature: 2020.. 2021, 3, e0590	0
389	Drug repurposing strategies and key challenges for COVID-19 management. 2021, 1-17	4
388	Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study.	

387	Characteristics and outcomes of hospitalized patients with cardiovascular complications of COVID-19.. 2021 , 13, 355-363	2
386	Colchicine use in patients with COVID-19: A systematic review and meta-analysis.. 2021 , 16, e0261358	4
385	Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. 2021 , 13, 14	4
384	Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: A self-controlled case series study.. 2022 ,	2
383	COVID-19 Treatment Options and Their Mechanism of Action up to Now: An Overview of Clinical Trials. 2022 , 30, 75-85	
382	An study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species.. 2022 , 41, 9603271221089257	1
381	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients.. 2022 , 13, 850583	1
380	Epigenetic regulation of autophagy in coronavirus disease 2019 (COVID-19).. 2022 , 30, 101264	
379	COVID-19 Related Fear, Risk Perceptions, and Behavioral Changes According to Level of Depression among Nursing Students.. 2022 , 19,	
378	Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.. 2022 , 9, 844728	3
377	Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports.. 2022 , 8, 14	1
376	Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study.. 2022 ,	0
375	Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.. 2022 , 1	1
374	Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19.	
373	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.. 2022 ,	0
372	Unraveling the binding mechanism of the active form of Remdesivir to RdRp of SARS-CoV-2 and designing new potential analogues: Insights from molecular dynamics simulations.. 2022 , 799, 139638	0
371	Data_Sheet_1.docx. 2020 ,	
370	Table_1.XLSX. 2020 ,	

369 Table_2.XLSX. 2020,

368 Table_3.XLSX. 2020,

367 Table_4.XLSX. 2020,

366 Table_5.xlsx. 2020,

365 Image_1.JPEG. 2020,

364 Image_2.JPEG. 2020,

363 Table_1.docx. 2020,

362 Data_Sheet_1.PDF. 2020,

361 Image_1.pdf. 2020,

360 Table_1.docx. 2020,

359 Image_1.pdf. 2021,

358 Table_1.docx. 2021,

357 Data_Sheet_1.PDF. 2020,

356 Table_1.DOCX. 2020,

355 Table_2.DOCX. 2020,

354 Table_3.DOCX. 2020,

353 Table_4.DOCX. 2020,

352 Table_5.DOCX. 2020,

351 Table_6.DOCX. **2020**,

350 Table_7.DOCX. **2020**,

349 Table_8.DOCX. **2020**,

348 DataSheet_1.xlsx. **2020**,

347 Table_1.XLSX. **2020**,

346 Table_2.XLSX. **2020**,

345 Image_1.JPEG. **2020**,

344 BET 1: The role of remdesivir in COVID-19 infection. **2020**, 37, 522.2-523

o

343 An Adaptive Information Borrowing Platform Design for Testing Drug Candidates of COVID-19.. **2022**, 2022, 9293681

342 A systematic review assessing the under-representation of cancer patients in COVID-19 trials.. **2022**, ,

341 Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.. **2021**, 20, 278-288

340 A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. **2021**, 13, 163

2

339 Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. **2022**, 33, 487-536

338 Mesenchymal stem cell therapy for COVID-19.. **2021**, 10, 79-89

337 Pharmacological Management. **2022**, 67-96

336 Low IFN- γ Response after Cell Stimulation Predicts Hospitalization in COVID-19 Patients.

335 Água e esgoto na pandemia da COVID-19: o papel da regulação e o desafio para o objetivo de desenvolvimento sustentável 6 no Brasil. **2022**, 27, 335-346

334 Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. **2022**, 17,

333	Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses.. 2022 , 16, e0010291		2
332	Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. 2022 , 12, 224-248		1
331	Optimizing antiviral therapy for COVID-19 with learned pathogenic model.. 2022 , 12, 6873		0
330	Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies. 2022 , 14, 1027		1
329	Effectiveness and Safety of Baidu Jieduan Granules for COVID-19: A Retrospective Observational Multicenter Study.. 2022 , 1		
328	PF-07321332 (Nirmatrelvir) Does Not Interact with Human ENT1 or ENT2: Implications for COVID-19 Patients.. 2022 ,		1
327	Efficacy of Remdesivir in the Intensive Care of Patients with COVID-19-associated Acute Respiratory Distress Syndrome. 2022 , 151-158		
326	Antiviral Drug Discovery for the Treatment of COVID-19 Infections. 2022 , 14, 961		3
325	Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany.. 2022 , 1		0
324	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.. 2022 , 13, 2576		3
323	Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an perspective.. 2022 , 17, 755-762		3
322	Emerging SARS-CoV-2 variants: why, how, and what's next?. 2022 , 100029		3
321	Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals. 2022 ,		1
320	Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics. 2022 , 13,		1
319	Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.. 2022 ,		0
318	Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.. <i>Lancet, The</i> , 2022 ,	40	25
317	Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.. 2022 ,		1
316	When and which patients should receive remdesivir?. <i>Lancet, The</i> , 2022 ,		40

315	Screening for inhibitors against SARS-CoV-2 and its variants.. 2022,	
314	Identification, optimization, and biological evaluation of 3-O-β-hacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein.. 2022, 238, 114426	2
313	Polymer nanoparticles (nanomedicine) for therapeutic applications. 2022, 71-123	
312	Clinical course of patients with severe COVID-19 pneumonia treated with remdesivir: A real-life study.. 2022, 17, e0267283	0
311	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. 2022, 20,	
310	The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.. 2022,	0
309	An Open, Prospective Cohort Study of VV116 in Chinese Participants Infected with SARS-CoV-2 Omicron Variants.. 2022, 1-22	7
308	When and How Will the Epidemic of COVID-19 End?. 2022, 13, 641	0
307	Yoga as a Potential Intervention for Preventing Cardiac Complications in COVID-19: Augmenting Immuno-Modulation and Bolstering Mental Health. 2022, 367-380	0
306	Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.	
305	Comparative evaluation of flavonoids reveals the superiority and promising inhibition activity of silibinin against SARS-CoV-2.	0
304	A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19.	1
303	Carbohydrate-based drugs launched during 2000-2021. 2022,	4
302	Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.	2
301	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. 2022, 203, 105345	1
300	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. 2022, 14, 1197	1
299	Remdesivir in the Treatment of COVID-19: A Propensity Score-Matched Analysis from a Public Hospital in New York City Assessing Renal and Hepatic Safety. 2022, 11, 3132	1
298	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. 2022,	5

297	Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.	7
296	Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir treated rhesus macaques. 2022 , 104448	0
295	Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. 2022 , 9,	3
294	Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients.	0
293	Comparison of efficacy of remdesivir with supportive care alone in the treatment of critically sick adult and child COVID-19 patients: A randomized clinical trial. 2022 , 20,	
292	A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. 2022 , 20,	1
291	Integrating Social Justice into the Chemistry Curriculum: Setting the Ethical Foundation for Future Scientists. 41-61	
290	Drug combination therapies for SARS-CoV-2 (COVID-19) treatment. 2022 , 181-203	
289	COVID-19 and its impact on cancer, HIV, and mentally ill patients. 2022 , 95-137	
288	SARS-CoV-2 and Therapeutic Approaches. 2022 , 2,	
287	Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review. 12,	1
286	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. 2022 ,	2
285	No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study. 1-10	0
284	Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. 2022 , 17, e0270196	0
283	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. 2022 , 12,	3
282	Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies. 12,	1
281	When might host heterogeneity drive the evolution of asymptomatic, pandemic coronaviruses?.	
280	Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal.	0

- 279 Lessons from SARS-CoV-2 and its variants (Review). **2022**, 26, 0
- 278 Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report. 0
- 277 Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. **2022**, 11, 805 0
- 276 Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. **2022**, 12, e057725 0
- 275 Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. **2022**, 12, 5
- 274 Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. **2022**, 14, 1345 2
- 273 The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. 9, 0
- 272 Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study. **2022**, 16, 216 0
- 271 A Transient Effect of Convalescent Plasma Therapy in a Patient with Severe Covonavirus Disease 2019: A Case Report. 54, 1
- 270 A virus target host proteins recognition method based on integrated complexes data and seed extension. **2022**, 23, 0
- 269 Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence. **2022**, 7, 287-302 0
- 268 Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in Brazil. **2022**, 0
- 267 Remdesivir in Very Old Patients (80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. **2022**, 11, 3769 1
- 266 Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. 13, 1
- 265 Threshold of increase in oxygen demand to predict mechanical ventilation use in novel coronavirus disease 2019: A retrospective cohort study incorporating restricted cubic spline regression. **2022**, 17, e0269876 0
- 264 Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). 0
- 263 A trial of arbidol hydrochloride in adults with COVID-19. Publish Ahead of Print, 0
- 262 Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. **2022**, 23, 7702 1

- 261 Predictive Risk Factors at Admission and a Burning Point During Hospitalization Serve as Sequential Alerts for Critical Illness in Patients With COVID-19. 9, 0
- 260 Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality. 0
- 259 Factors Affecting SARS-CoV-2 Variant Distribution in Military Hospitals in Jordan. 2022, 115771
- 258 The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. 2022, 13, 1101-1110 0
- 257 Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
- 256 Clinical research capability enhanced for medical undergraduates: an innovative simulation-based clinical research curriculum development. 2022, 22,
- 255 Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. 2200060 0
- 254 An Ordinal Severity Scale for COVID-19 Retrospective Studies Using Electronic Health Record Data. 0
- 253 Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2. 2022, 20, 0
- 252 Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma. 2022, 25, 27-35 0
- 251 Herbal approach for the management of COVID-19: an overview. 2021, 36, 1-8 0
- 250 Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. 2022, 19, 8845 1
- 249 COVID-19 and liver diseases. 2022, 12, 0
- 248 Remdesivir-Induced Marked Sinus Bradycardia in COVID-19. 2022,
- 247 A narrative review on yoga: a potential intervention for augmenting immunomodulation and mental health in COVID-19. 2022, 22, 0
- 246 Antiviral activity of medicinal plant-derived products against SARS-CoV-2. 153537022211089 2
- 245 Don't Look Up Your Science Herd Immunity or Herd Mentality?. 2022, 10, 1463
- 244 Gastrointestinal prophylaxis for COVID-19: An illustration of severe bias arising from inappropriate comparators in observational studies. 2022,

243	Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. 2022 , 58, 1007	0
242	Practical and Highly Efficient Synthesis of Remdesivir from GS-441524.	1
241	Respiratory Tract Infections in Diabetes [Lessons From Tuberculosis and Influenza to Guide Understanding of COVID-19 Severity. 13,	1
240	The COVID-19 Pandemic and HIV. 2021 , 425-428	
239	COVID-19 Treatments Based on Pathogenicity. 2022 , 11, 122-127	
238	A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic.	1
237	Interpretable Personalized Experimentation. 2022 ,	0
236	The effects of nutrition bio-shield superfood powder on immune system function: A clinical trial study among patients with COVID-19. 13,	
235	Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.	3
234	Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia. 2022 ,	
233	Managing Rheumatic Diseases in COVID-19. 2022 , 32, 159-165	
232	Absolute binding free energies of mucroporin and its analog mucroporin-M1 with the heptad repeat 1 domain and RNA-dependent RNA polymerase of SARS-CoV-2. 1-12	
231	Azithromycin through the Lens of the COVID-19 Treatment. 2022 , 11, 1063	1
230	Identifying inhibitors of NSP16-NSP10 of SARS-CoV-2 from large databases. 1-10	
229	Characterization of Pathogen Inactivated COVID -19 Convalescent Plasma and Responses in Transfused Patients.	0
228	Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review. Publish Ahead of Print,	0
227	RK-33, a small molecule inhibitor of host RNA helicase DDX3, suppresses multiple variants of SARS-CoV-2. 13,	1
226	Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.	0

225	Joint inference for competing risks data using multiple endpoints.	
224	Treatments for the Infection by SARS-CoV-2.	
223	Care of the Seriously Ill Patient with SARS CoV-2. 2022,	
222	Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review. Volume 15, 4457-4466	2
221	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. 10,	
220	A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease.	
219	Two Years into the COVID-19 Pandemic: Lessons Learned.	4
218	Optimal COVID-19 therapeutic candidate discovery using the CANDO platform. 13,	0
217	Identifying potential pharmacological targets and mechanisms of vitamin D for hepatocellular carcinoma and COVID-19. 13,	
216	Comparison of treatments with ordinal responses in trials with sequential monitoring and response-adaptive randomization.	
215	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). 2022,	
214	Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial. 9,	1
213	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis.	1
212	Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19.	1
211	Major Update 2: Remdesivir for Adults With COVID-19. 2022, 175, W81	0
210	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination.	3
209	AN EVALUATION OF ADVERSE DRUG REACTIONS WITH REMDESIVIR IN PATIENTS OF COVID-19. 88-91	0
208	Protein Kinase C Inhibitors Reduce SARS-CoV-2 Replication in Cultured Cells.	0

207	Nonproductive exposure of PBMCs to SARS-CoV -2 induces cell-intrinsic innate immune responses. 2022 , 18,	1
206	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. 2022 , 111, 109161	2
205	Consequences of COVID-19 on the cardiovascular and renal systems. 2022 , 100, 31-38	0
204	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. 2022 , 29,	2
203	MultiOMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells.	0
202	COVID-19 in patients with B cell immune deficiency. 2022 , 510, 113351	0
201	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. 2022 , 4, 100054	0
200	Evaluation of COVID-19 treatments in Iran in comparison with local therapeutic recommendations: A population-level study on utilization and costs of prescription drugs. 2022 , 11, 1	0
199	Genomic Approaches for Drug Repositioning. 2022 , 49-72	0
198	Pre-hospital Management of COVID-19: Looking for a Future Perspective. 2022 , 395-419	0
197	Genetics and Biological Characteristics of SARS-CoV-2. 2022 , 49-66	0
196	Pulmonary Phospholipid Components as Promising Natural Inhibitors against COVID-19 Mpro; Molecular Docking Analysis Based Study. 2022 , 34, 2191-2197	0
195	Safety and sagacious use of remdesivir: Paramount focus on contemporary perspectives. 2022 , 6, 1	0
194	Herbs and drugs in clinical trials for coronavirus treatments. 2022 , 55-70	0
193	Elucidating the pathogenicity, diagnosis, treatment, and prevention of COVID-19: Part I. 2022 , 13, 127	0
192	Remdesivir-Induced Pancreatitis in a Patient With Coronavirus Disease 2019. 2022 , 51, e88-e89	0
191	Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study. 2022 , 11, 5066	0
190	COVID-19 and Cardiovascular Manifestations. 2022 , 102-136	0

189	Effect of Remdesivir Administration on Occurrence of Major Adverse Cardiac Events in Critically Ill COVID-19 Pneumonia: A Retrospective Observational Study. 2022 , 26, 993-999	0
188	A novel logical model of COVID-19 intracellular infection to support therapies development. 2022 , 18, e1010443	0
187	Outpatient Management of COVID-19: A Primer for the Dermatologist.	0
186	Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies. 2022 , 50,	2
185	Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era. 2022 , 14, 4252	0
184	COVID-19 and Pulmonary Diseases. 2022 , 230-262	0
183	Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues. 2203388	1
182	Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. 13,	0
181	Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study. 1-15	3
180	Low baseline IFN- γ response could predict hospitalization in COVID-19 patients. 13,	1
179	Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized Patients with COVID-19: impact on the length of hospital stay and mortality.	0
178	Political Prescriptions: Three Pandemic Stories. 016224392211238	0
177	Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. 2022 , 14, 4720	4
176	Clinical Profile and Outcomes of Multisystem Inflammatory Syndrome in Children: A Multicentric Observational Study. 2022 ,	0
175	Targeting intracellular Neu1 for Coronavirus Infection Treatment.	0
174	COVID-19 Salivary Protein Profile: Unravelling Molecular Aspects of SARS-CoV-2 Infection. 2022 , 11, 5571	0
173	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.	0
172	Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.	1

171	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. 00236-2022	0
170	Antiviral activity of Cenostigma pluviosum var. peltophoroides extract and fractions against SARS-CoV-2. 1-12	1
169	Effects of COVID-19 on Arrhythmia. 2022 , 9, 292	0
168	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. 2022 , 12, 1472	0
167	Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. 1-14	2
166	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. 1-21	1
165	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.	0
164	Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. 2022 , 23,	0
163	Pharmacokinetic Considerations to Optimize Clinical Outcomes for COVID-19 Drugs. 2022 ,	0
162	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
161	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. 2022 , 217, 368-378	1
160	Immunophenotyping Characteristics of COVID-19 Patients: Peripheral Blood CD8+ HLA-DR+ T Cells as a Biomarker for Mortality Outcome.	0
159	Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19. 2022 , 9, e00866	0
158	Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study.	1
157	Evaluation of the efficacy and safety of remdesivir in hospitalized patients with a new coronavirus infection COVID-19: data from a Russian university clinic. 2022 , 152-160	0
156	Identification of SARS-CoV-2 spike protein inhibitors from urtica dioica to develop herbal-based therapeutics against COVID-19. 2022 , 0	0
155	COVID-19: Lesson Learnt from Diagnostics to Therapeutics. 2022 , 345-374	0
154	Japanese rapid/living recommendations on drug management for COVID -19: updated guidelines (July 2022). 2022 , 9,	0

153	Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review. 2022 , 9, 47	0
152	Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19. 2022 , 35, 106-110	0
151	Misinformation about medication during the COVID-19 pandemic: A perspective of medical staff. 2022 , 17, e0276693	1
150	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. 2022 , 12, 1605	2
149	Synthesis of Nucleoside and Nucleotide Analogues by Cyclization of the Guanine Base with 1,1,3,3-Tetramethoxypropane. 2022 , 24, 7834-7838	0
148	Technical Data of In Silico Analysis of the Interaction of Dietary Flavonoid Compounds against Spike-Glycoprotein and Proteases of SARS-CoV-2. 2022 , 7, 144	0
147	Severe COVID-19 Pneumonia in an Unvaccinated Female Treated With Remdesivir. 2022 ,	0
146	Mucus-Inspired Tribology, a Sticky Yet Flowing Hydrogel.	0
145	Effect of Remdesivir on moderate to severe COVID-19 patients' outcomes..	0
144	The efficacy and safety of remdesivir and its combination with other drug for the treatment of COVID-19: a systematic review and meta-analysis.	0
143	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13,	1
142	Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. 2022 , 5, e2238354	6
141	COVID-19 Therapeutics and Considerations for Pregnancy. 2022 ,	0
140	Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants.	1
139	Translocation pause of remdesivir-containing primer/template RNA duplex within SARS-CoV-2 RNA polymerase complexes. 9,	0
138	Evaluation of Drug-Induced Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection. 2022 , 10, 2045	1
137	Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2. 2022 , 12, 1706	0
136	Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial. 2022 , 100653	0

- 135 The pharmaceutical industry is dangerous to health. Further proof with COVID-19. 13, 475 ○
- 134 Anti-COVID-19 Traditional Chinese Medicine database. **2022**, 04, ○
- 133 How pragmatic are randomized trials of Remdesivir and Favipiravir for in-hospital treatment of Covid-19: A descriptive methodological review of trial design using the PRECIS-2 framework. **2022**, ○
- 132 COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12 ○
- 131 Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: A retrospective multicenter study. **2022**, 16, 100207 ○
- 130 A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. **2022**, 12, 1758 2
- 129 Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. **2023**, 130, 106264 ○
- 128 Strategies for delivery of antiviral agents. **2023**, 407-492 ○
- 127 A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. 12, ○
- 126 Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan. **2022**, ○
- 125 Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). **2022**, 11, 6545 ○
- 124 Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. **2022**, 29, ○
- 123 A country-based review in COVID-19 related research developments. ○
- 122 Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir. ○
- 121 Risk factors and mortality of pulmonary embolism in COVID-19 patients: Evidence based on fifty observational studies. **2022**, 101, e29895 ○
- 120 The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a casecontrol study. **2022**, 21, ○
- 119 How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea. **2022**, 37, ○
- 118 Arzneimittelnutzung unter Pandemiebedingungen. **2022**, 171-187 ○

117	Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. 2023 , 157, 114037	0
116	COVID 19: Airway Management and Pharmacological Strategies. 2022 , 06, 210-215	0
115	Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. 2022 , 27, 8257	1
114	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. 13,	0
113	Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. 2022 , 23, 14462	0
112	Lung Transplantation for COVID-19 Pulmonary Sequelae. Publish Ahead of Print,	0
111	Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection. 11, 435-442	0
110	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. 13,	0
109	Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands. 2022 , 9,	1
108	Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. 13,	1
107	Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review. 28, 6662-6688	0
106	SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease.	0
105	Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. 2022 ,	0
104	An In-Silico Multi-Targeted Approach in Search of Potential Drug Candidate(s) Against SARS-CoV-2 Lung Infection. 2022 , 04,	0
103	Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses.	0
102	Small molecules in the treatment of COVID-19. 2022 , 7,	3
101	The Use and Safety Risk of Repurposed Drugs for COVID-19 patients: Lessons Learned Utilizing the Food and Drug Administration's Adverse Event Reporting System.	0
100	CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY. 2022 , 10, 432-445	1

- 99 An efficacy and safety report based on randomized controlled single-blinded multi-centre clinical trial of ZingiVir-H, a novel herbo-mineral formulation designed as an add-on therapy in adult patients with mild to moderate COVID-19. **2022**, 17, e0276773 ○
- 98 Clinical outcomes of COVID-19 caused by the Alpha variant compared with one by wild type in Kobe, Japan. A multi-center nested case-control study. **2022**, ○
- 97 Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. **2022**, 2, 1758-1767 ○
- 96 SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. **2022**, 10, 2145 1
- 95 Repurposing of Chemotherapeutics to Combat COVID-19. **2022**, 22, 2660-2694 1
- 94 Developing a Conceptual Model with Policy Implications to Better Support Healthcare Providers Working with Older Adults during a Pandemic: An Interpretive Descriptive Qualitative Study. 073346482211436 0
- 93 Liver disease during the pandemic of COVID-19 infection: prediction of the course and tactics of management: A review. **2022**, 94, 1326-1332 ○
- 92 Therapeutic potential of compounds targeting SARS-CoV-2 helicase. 10, ○
- 91 Cardiovascular Side Effects of Neuraminidase Inhibitors: A Review. **2023**, 10-17 ○
- 90 Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases. **2022**, 1 1
- 89 Misinterpretation of statistical nonsignificance as a sign of potential bias: Hydroxychloroquine as a case study. 1-20 ○
- 88 Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors. **2023**, 28, 160 ○
- 87 Multi-Targeting Approach in Selection of Potential Molecule for COVID-19 Treatment. **2023**, 15, 213 ○
- 86 Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients. **2023**, 13, 99 ○
- 85 COVID-19 and hepatic injury: Diversity and risk assessment. 29, 425-449 ○
- 84 Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. **2023**, 102189 ○
- 83 Multi-OMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells. **2023**, 26, 105895 ○
- 82 Commentary on COVID-19-induced liver injury in various age and risk groups. 12, 44-52 ○

81	Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine. 2023 , 27, 6-14	0
80	Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature. 2023 , 11, 176	1
79	Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. 29, 241-256	0
78	The evidence base for emergency use authorizations for COVID-19 treatments: A rapid review. 2023 , 6,	0
77	6-Shogaol Exhibits Anti-viral and Anti-inflammatory Activity in COVID-19-Associated Inflammation by Regulating NLRP3 Inflammasomes. 2023 , 8, 2618-2628	1
76	Spray freeze dried niclosamide nanocrystals embedded dry powder for high dose pulmonary delivery. 2023 , 415, 118168	0
75	Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score. 2023 , 78, 102188	0
74	Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. 2022 , 17, e0278963	0
73	Experience of Using Remdesivir in Patients with Novel Coronavirus Infection. 2022 , 10, 365-380	0
72	Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19. 2022 , 100010	0
71	Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. 2022 , 21, 1483-1494	0
70	Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review. 2022 , 10, 326-344	0
69	COVID-19: Inpatient Management. 2023 , 182-232	0
68	Evaluation of Convalescent Plasma in the Management of Critically Ill COVID-19 Patients (with No Detectable Neutralizing Antibodies Nab) in Kashmir, India. 2023 , 11, 317	1
67	miRNAomics in COVID-19. 2023 , 145-160	0
66	SARS-CoV-2 Neutralizing Antibody Therapies: Early retrospective cohort study of 26 hospitalized patients treated with Bamlanivimab or Casirivimab/Imdevimab. 2023 ,	0
65	COVID-19: Diabetes Perspective Pathophysiology and Management. 2023 , 12, 184	1
64	Coronavirus Pandemics. 2023 , 143-222	0

- 63 Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. **2023**, 15, 451 ○
- 62 Acute Inflammatory Recovery: A Matter of Sophisticated Interaction of Two Cell Populations?. **2023**, 107, 289-290 ○
- 61 Use of Remdesivir in children with COVID-19: report of an Italian multicenter study. ○
- 60 Risk of Mortality in Bone Marrow Transplant Patients During SARS-CoV-2 Infection: A Systematic Review. **2023**, 21, 1-11 ○
- 59 The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells. **2023**, 15, 332 ○
- 58 Remdesivir for the treatment of COVID-19. **2023**, 2023, ○
- 57 Belimumab for the treatment of pediatric patients with lupus nephritis. ○
- 56 Emerging Novel Therapies for COVID-19: Implications for the Use of Nitric Oxide as an Anti-COVID-19 Therapy. **2023**, 259-278 ○
- 55 Efficacy and Adverse Effects of Remdesivir in Patients with COVID-19 Pneumonia: A Retrospective Study. ○
- 54 Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. **2023**, 31, 517-525 ○
- 53 Predictors of intensive care unit length of stay and mortality among unvaccinated COVID-19 patients in Jordan. **2023**, 5, 100278 ○
- 52 Repurposing of Ruxitinib showed effective treatment for COVID-19 disease. ○
- 51 Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. **2023**, 58, 101889 ○
- 50 Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience. **2023**, 9, e13126 ○
- 49 Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors. **2023**, 80, 117179 1
- 48 Targeting intracellular Neu1 for coronavirus infection treatment. **2023**, 26, 106037 ○
- 47 The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19. 2, ○
- 46 The development of COVID-19 treatment. 14, 2

- 45 Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19. **2023**, 3, 198-217 ○
- 44 Impact of COVID-19 on Patients with Decompensated Liver Cirrhosis. **2023**, 13, 600 ○
- 43 An overview on the treatments and prevention against COVID-19. **2023**, 20, ○
- 42 Relation of COVID-19 with liver diseases and their impact on healthcare systems: The Portuguese case. 29, 1109-1122 ○
- 41 COVID-19 and liver injury in individuals with obesity. 29, 908-916 ○
- 40 Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. ○
- 39 Impact of COVID-19 on Cardiovascular Disease. **2023**, 15, 508 ○
- 38 Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID-19?. **2023**, 23, ○
- 37 Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. **2023**, 6, e2255815 ○
- 36 Lung Injury in COVID-19 Has Pulmonary Edema as an Important Component and Treatment with Furosemide and Negative Fluid Balance (NEGBAL) Decreases Mortality. **2023**, 12, 1542 ○
- 35 Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. **2023**, 13, 309 ○
- 34 Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce. **2023**, ○
- 33 Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: A Joint Evidence-Based Guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). ○
- 32 Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. **2023**, ○
- 31 An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. **2023**, 9, e13952 ○
- 30 A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine. **2023**, 11, 515 ○
- 29 Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages. **2023**, 9, e14059 ○
- 28 Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID19) - Analysis of data from daily practice. ○

- 27 We Can Think About Ourselves The Computer Cannot. **2023**, 197-211 ○
- 26 Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. **2023**, 28, 2332 ○
- 25 Oral Pathology in the Context of COVID-19: Perspectives Based on a Compilation of Literature Data. **2020**, 48, 517-531 ○
- 24 The main treatments used for SARS-CoV-2 patients. **2022**, 3, 095-103 ○
- 23 Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. **2023**, 55, 351-360 ○
- 22 Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. 10, ○
- 21 Modulation of gut microbiota as a potential therapy to manipulate drug-induced hepatic damage in COVID-19 patients. 29, 1708-1720 ○
- 20 SARS-COV-2 Spike Protein: Characteristics and Treatments. 36, 859-865 ○
- 19 Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. 14, ○
- 18 Outpatient medications associated with protection from COVID-19 hospitalization. **2023**, 18, e0282961 ○
- 17 Treatment options for patients with severe COVID-19. **2023**, ○
- 16 Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. **2023**, 1-16 ○
- 15 Current Strategies to Combat COVID-19. **2023**, 361-374 ○
- 14 Safety and Efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial. **2023**, 100706 ○
- 13 Repurposing of Ratan showed effective treatment for COVID-19 disease. ○
- 12 Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. **2023**, 11, 1000 ○
- 11 Acute kidney injury in COVID-19 patients receiving remdesivir: a systematic review and meta-analysis of randomized clinical trials. **2023**, 100200 ○
- 10 A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. **2023**, 9, ○

- 9 Acute kidney injury in critically ill patients with COVID-19: The AKICOV multicenter study in Catalonia 2023, 18, e0284248 ○
- 8 Severe COVID-19: Drugs and Clinical Trials. 2023, 12, 2893 ○
- 7 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ○
- 6 DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19. 2023, 106969 ○
- 5 Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study. ○
- 4 The importance of outpatient etiotropic therapy in patients hospitalized with COVID-19. 2023, 15, 48-54 ○
- 3 Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection. 2023, ○
- 2 Viral dynamics of SARS-CoV-2 in immunocompromised patients. 2023, ○
- 1 COMPARISON OF THE EFFECTIVENESS OF REMDESIVIR VERSUS FAVIPIRAVIR ON CLINICAL IMPROVEMENT AND MORTALITY AMONG PATIENTS WITH COVID-19 PNEUMONIA: A RETROSPECTIVE SINGLE-CENTER STUDY. 7, e0151 ○